Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Volker Diehl

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Hodgkin Disease

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Living Beings

Mice

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Engert Andreas; Diehl Volker; Franklin Jeremy; Lohri Andreas; Dörken Bernd; Ludwig Wolf-Dieter; Koch Peter; Hänel Mathias; Pfreundschuh Michael; Wilhelm Martin; Trümper Lorenz; Aulitzky Walter-Erich; Bentz Martin; Rummel Mathias; Sezer Orhan; Müller-Hermelink Hans-Konrad; Hasenclever Dirk; Löffler Markus
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Rautert Roger; Schinköthe Timo; Franklin Jeremy; Weihrauch Martin; Boll Boris; Pogge Elke; Bredenfeld Henning; Engert Andreas; Diehl Volker; Re Daniel
Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma.
Kobe Carsten; Dietlein Markus; Franklin Jeremy; Markova Jana; Lohri Andreas; Amthauer Holger; Klutmann Susanne; Knapp Wolfram H; Zijlstra Josee M; Bockisch Andreas; Weckesser Matthias; Lorenz Reinhard; Schreckenberger Mathias; Bares Roland; Eich Hans T; Mueller Rolf-Peter; Fuchs Michael; Borchmann Peter; Schicha Harald; Diehl Volker; Engert Andreas
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Volker Diehl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Engert Andreas; Diehl Volker; Franklin Jeremy; Lohri Andreas; Dörken Bernd; Ludwig Wolf-Dieter; Koch Peter; Hänel Mathias; Pfreundschuh Michael; Wilhelm Martin; Trümper Lorenz; Aulitzky Walter-Erich; Bentz Martin; Rummel Mathias; Sezer Orhan; Müller-Hermelink Hans-Konrad; Hasenclever Dirk; Löffler Markus
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(27):4548-54.
2008: Rautert Roger; Schinköthe Timo; Franklin Jeremy; Weihrauch Martin; Boll Boris; Pogge Elke; Bredenfeld Henning; Engert Andreas; Diehl Volker; Re Daniel
Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma.
Leukemia & lymphoma 2008;49(11):2091-8.
2008: Kobe Carsten; Dietlein Markus; Franklin Jeremy; Markova Jana; Lohri Andreas; Amthauer Holger; Klutmann Susanne; Knapp Wolfram H; Zijlstra Josee M; Bockisch Andreas; Weckesser Matthias; Lorenz Reinhard; Schreckenberger Mathias; Bares Roland; Eich Hans T; Mueller Rolf-Peter; Fuchs Michael; Borchmann Peter; Schicha Harald; Diehl Volker; Engert Andreas
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Blood 2008;112(10):3989-94.
2008: Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(10):1795-801.
2008: Nogová Lucia; Reineke Thorsten; Brillant Corinne; Sieniawski Michal; Rüdiger Thomas; Josting Andreas; Bredenfeld Henning; Skripnitchenko Roman; Müller Rolf-Peter; Müller-Hermelink Hans-Konrad; Diehl Volker; Engert Andreas;
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):434-9.
2008: Schulz Holger; Rehwald Ute; Morschhauser Franck; Elter Thomas; Driessen Christoph; Rüdiger Thomas; Borchmann Peter; Schnell Roland; Diehl Volker; Engert Andreas; Reiser Marcel
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).
Blood 2008;111(1):109-11.
2008: Sieniawski Michal; Reineke Thorsten; Nogova Lucia; Josting Andreas; Pfistner Beate; Diehl Volker; Engert Andreas
Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
Blood 2008;111(1):71-6.
2008: Macann Andrew; Bredenfeld Henning; Müller Rolf-Peter; Diehl Volker; Engert Andreas; Eich Hans Theodor
Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Study Group.
International journal of radiation oncology, biology, physics 2008;70(1):161-5.
2007: Eich Hans Theodor; Gossmann Axel; Engert Andreas; Kriz Jan; Bredenfeld Henning; Hansemann Katja; Skripnitchenko Roman; Brillant Corinne; Pfistner Beate; Staar Susanne; Diehl Volker; Müller Rolf-Peter;
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
International journal of radiation oncology, biology, physics 2007;69(4):1187-92.
2007: Diehl Volker; Fuchs Michael;
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2007;37(1):37-41.
2007: Engert Andreas; Franklin Jeremy; Eich Hans Theodor; Brillant Corinne; Sehlen Susanne; Cartoni Claudio; Herrmann Richard; Pfreundschuh Michael; Sieber Markus; Tesch Hans; Franke Astrid; Koch Peter; de Wit Maike; Paulus Ursula; Hasenclever Dirk; Loeffler Markus; Müller Rolf-Peter; Müller-Hermelink Hans Konrad; Dühmke Eckhart; Diehl Volker
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3495-502.
2007: Diehl V; Fuchs M
Early, intermediate and advanced Hodgkin's lymphoma: modern treatment strategies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 9():ix71-9.
2007: Sieniawski Michal; Franklin Jeremy; Nogova Lucia; Glossmann Jan-Peter; Schober Thomas; Nisters-Backes Hiltrud; Diehl Volker; Josting Andreas
Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2000-5.
2007: Sieniawski Michal; Staak Oliver; Glossmann Jan-Peter; Reineke Thorsten; Scheuss Helena; Diehl Volker; Engert Andreas; Josting Andreas
Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
Annals of hematology 2007;86(2):107-15.
2007: Klimm B; Eich H T; Haverkamp H; Lohri A; Koch P; Boissevain F; Trenn G; Worst P; Dühmke E; Müller R P; Müller-Hermelink K; Pfistner B; Diehl V; Engert A;
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):357-63.
2007: Schwonzen Martin; Diehl Volker; Dellanna Mario; Staib Peter
Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis.
Leukemia research 2007;31(1):113-6.
2007: Wilde Stefan; Jetter Alexander; Rietbrock Stephan; Kasel Dirk; Engert Andreas; Josting Andreas; Klimm Beate; Hempel Georg; Reif Stefanie; Jaehde Ulrich; Merkel Ute; Busse Dagmar; Schwab Matthias; Diehl Volker; Fuhr Uwe
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.
Clinical pharmacokinetics 2007;46(4):319-33.
2006: Franklin J; Pluetschow A; Paus M; Specht L; Anselmo A-P; Aviles A; Biti G; Bogatyreva T; Bonadonna G; Brillant C; Cavalieri E; Diehl V; Eghbali H; Fermé C; Henry-Amar M; Hoppe R; Howard S; Meyer R; Niedzwiecki D; Pavlovsky S; Radford J; Raemaekers J; Ryder D; Schiller P; Shakhtarina S; Valagussa P; Wilimas J; Yahalom J
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(12):1749-60.
2006: Diehl V; Behringer K
Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Cancer investigation 2006;24(4):461-5.
2006: Draube Andreas; Behringer Karolin; Diehl Volker
German Hodgkin's Lymphoma Study Group trials: lessons from the past and current strategies.
Clinical lymphoma & myeloma 2006;6(6):458-68.
2006: Engert Andreas; Bredenfeld Henning; Döhner Hartmut; Ho Anthony D; Schmitz Norbert; Berger Dietmar; Bacon Pamela; Skacel Tomas; Easton Valerie; Diehl Volker
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study.
Haematologica 2006;91(4):546-9.
2006: Borchmann P; Behringer K; Josting A; Rueffer J U; Schnell R; Diehl V; Engert A; Kvasnicka H M; Thiele J
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]
Der Pathologe 2006;27(1):47-52.
2005: Rödel Susanne; Engert Andreas; Diehl Volker; Reiser Marcel
Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long-term survival in patients with aggressive malignant non-Hodgkin's lymphomas: long-term follow-up of a pilot study.
Leukemia & lymphoma 2005;46(12):1729-34.
2005: Klimm Beate; Schnell Roland; Diehl Volker; Engert Andreas
Current treatment and immunotherapy of Hodgkin's lymphoma.
Haematologica 2005;90(12):1680-92.
2005: Rüffer J U; Ballova V; Glossmann J; Sieber M; Franklin J; Nogova L; Diehl V; Josting A;
BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
Leukemia & lymphoma 2005;46(11):1561-7.
2005: Klimm Beate; Reineke Thorsten; Haverkamp Heinz; Behringer Karolin; Eich Hans T; Josting Andreas; Pfistner Beate; Diehl Volker; Engert Andreas;
Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8003-11.
2005: Eich Hans Theodor; Haverkamp Uwe; Engert Andreas; Kocher Martin; Skripnitchenko Roman; Brillant Corinne; Sehlen Susanne; Dühmke Eckhart; Diehl Volker; Müller Rolf-Peter
Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
International journal of radiation oncology, biology, physics 2005;63(3):860-5.
2005: Behringer Karolin; Breuer Kai; Reineke Thorsten; May Michael; Nogova Lucia; Klimm Beate; Schmitz Tatiana; Wildt Ludwig; Diehl Volker; Engert Andreas;
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7555-64.
2005: Nogová L; Reineke T; Eich H T; Josting A; Müller-Hermelink H K; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen M V; Müller R-P; Diehl V; Engert A
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(10):1683-7.
2005: Weihrauch Martin R; Ansén Sascha; Jurkiewicz Elke; Geisen Caroline; Xia Zhinan; Anderson Karen S; Gracien Edith; Schmidt Manuel; Wittig Burghardt; Diehl Volker; Wolf Juergen; Bohlen Heribert; Nadler Lee M
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5993-6001.
2005: Shimabukuro-Vornhagen Alexander; Haverkamp Heinz; Engert Andreas; Balleisen Leopold; Majunke Peter; Heil Günther; Eich Hans Theodor; Stein Harald; Diehl Volker; Josting Andreas
Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5739-45.
2005: Engert Andreas; Ballova Veronika; Haverkamp Heinz; Pfistner Beate; Josting Andreas; Dühmke Eckhart; Müller-Hermelink Konrad; Diehl Volker;
Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5052-60.
2005: Josting A; Sieniawski M; Glossmann J-P; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1359-65.
2005: Glossmann Jan-Peter; Staak Jan Oliver; Nogova Lucia; Diehl Volker; Scheid Christoph; Kisro Jens; Reis Hans-Edgar; Peter Norma; Engert Andreas; Josting Andreas
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Annals of hematology 2005;84(8):517-25.
2005: Schnell Roland; Dietlein Markus; Staak Jan Oliver; Borchmann Peter; Schomaecker Klaus; Fischer Thomas; Eschner Wolfgang; Hansen Hinrich; Morschhauser Franck; Schicha Harald; Diehl Volker; Raubitschek Andrew; Engert Andreas
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4669-78.
2005: Smardova L; Engert A; Haverkamp H; Raemakers Jm; Baars Jw; Pfistner B; Diehl V; Josting A
Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
Leukemia & lymphoma 2005;46(7):1017-22.
2005: Klimm Beate; Diehl Volker; Pfistner Beate; Engert Andreas
Current treatment strategies of the German Hodgkin Study Group (GHSG).
European journal of haematology. Supplementum 2005;(66):125-34.
2005: Nogová Lucia; Reineke Thorsten; Josting Andreas; Müller-Hermelink Hans K; Eich Hans T; Behringer Karolin; Müller Rolf-Peter; Diehl Volker; Engert Andreas
Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
European journal of haematology. Supplementum 2005;(66):106-10.
2005: Gossmann Axel; Eich Hans Theodor; Engert Andreas; Josting Andreas; Müller Rolf-Peter; Diehl Volker; Lackner Klaus-Jürgen
CT and MR imaging in Hodgkin's disease--present and future.
European journal of haematology. Supplementum 2005;(66):83-9.
2005: Weihrauch Martin R; Manzke Oliver; Beyer Marc; Haverkamp Heinz; Diehl Volker; Bohlen Heribert; Wolf Juergen; Schultze Joachim L
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Cancer research 2005;65(13):5516-9.
2005: Thiele Juergen; Kvasnicka Hans Michael; Diehl Volker
Bone marrow features of diagnostic impact in erythrocytosis.
Annals of hematology 2005;84(6):362-7.
2005: Re Daniel; Thomas Roman K; Behringer Karolin; Diehl Volker
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.
Blood 2005;105(12):4553-60.
2005: Thiele Juergen; Kvasnicka Hans Michael; Diehl Volker
Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients.
Leukemia & lymphoma 2005;46(5):709-15.
2005: Thiele J; Kvasnicka H M; Diehl V
Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns?
Histology and histopathology 2005;20(2):633-44.
2005: Josting Andreas; Nogová Lucia; Franklin Jeremy; Glossmann Jan-Peter; Eich Hans Theodor; Sieber Markus; Schober Thomas; Boettcher Heinz-Dietrich; Schulz Ulrich; Müller Rolf-Peter; Diehl Volker; Engert Andreas
Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(7):1522-9.
2005: Klimm Beate; Engert Andreas; Diehl Volker
First-line treatment of Hodgkin's lymphoma.
Current hematology reports 2005;4(1):15-22.
2005: Ballova V; Rüffer J-U; Haverkamp H; Pfistner B; Müller-Hermelink H K; Dühmke E; Worst P; Wilhelmy M; Naumann R; Hentrich M; Eich H T; Josting A; Löffler M; Diehl V; Engert A
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):124-31.
2005: Josting A; Rudolph C; Mapara M; Glossmann J-P; Sieniawski M; Sieber M; Kirchner H H; Dörken B; Hossfeld D K; Kisro J; Metzner B; Berdel W E; Diehl V; Engert A
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):116-23.
2005: Thiele Jurgen; Kvasnicka Hans Michael; Diehl Volker
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia.
Acta haematologica 2005;113(4):213-9.
2005: Knaebel H P; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler M W
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
BMC cancer 2005;5():37.
2004: Schneider Eva-Maria; Torlakovic Emina; Stühler Albert; Diehl Volker; Tesch Hans; Giebel Bernd
The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma.
The Journal of pathology 2004;204(5):538-45.
2004: Klimm Beate; Engert Andreas; Diehl Volker;
Axillary swelling and a reduced general condition in a middle-aged man.
Nature clinical practice. Oncology 2004;1(1):51-4; quiz 1 p following 54.
2004: Weihrauch M R; Diehl V
Artificial sweeteners--do they bear a carcinogenic risk?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(10):1460-5.
2004: Thiele J; Kvasnicka H M; Zerhusen G; Vardiman J; Diehl V; Luebbert M; Schmitt-Graeff A
Acute panmyelosis with myelofibrosis: a clinicopathological study on 46 patients including histochemistry of bone marrow biopsies and follow-up.
Annals of hematology 2004;83(8):513-21.
2004: Behringer K; Josting A; Schiller P; Eich H T; Bredenfeld H; Diehl V; Engert A;
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1079-85.
2004: Thomas Roman K; Wickenhauser Claudia; Tawadros Samir; Diehl Volker; Küppers Ralf; Wolf Jürgen; Schmitz Roland
Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma.
British journal of haematology 2004;126(1):50-4.
2004: Eich Hans Theodor; Staar Susanne; Gossmann Axel; Engert Andreas; Franklin Jeremy; Sieber Markus; Krug Barbara; Diehl Volker; Lackner Klaus-Jürgen; Müller Rolf-Peter;
The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): a quality assurance program based on a multidisciplinary panel reviewing all patients' imaging.
American journal of clinical oncology 2004;27(3):279-84.
2004: Hartmann Pia; Rehwald Ute; Salzberger Bernd; Franzen Caspar; Diehl Volker
Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection.
Expert review of anticancer therapy 2004;4(3):401-10.
2004: Bredenfeld Henning; Franklin Jeremy; Nogova Lucia; Josting Andreas; Fries S; Mailänder Volker; Oertel Joachim; Diehl Volker; Engert Andreas;
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2424-9.
2004: Heuser Claudia; Guhlke Stefan; Matthies Alexander; Bender Hans; Barth Stefan; Diehl Volker; Abken Hinrich; Hombach Andreas
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
International journal of cancer. Journal international du cancer 2004;110(3):386-94.
2004: Thomas Roman K; Wickenhauser Claudia; Kube Dieter; Tesch Hans; Diehl Volker; Wolf Jürgen; Vockerodt Martina
Repeated clonal relapses in classical Hodgkin's lymphoma and the occurrence of a clonally unrelated diffuse large B cell non-Hodgkin lymphoma in the same patient.
Leukemia & lymphoma 2004;45(5):1065-9.
2004: Weihrauch Martin R; Staib Peter; Seiberlich Bettina; Hoffmann Martin; Diehl Volker; Tesch Hans
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Leukemia & lymphoma 2004;45(4):699-704.
2004: Herrmann-Frank A; Diehl V
[Malignant lymphoma competence network]
Der Internist 2004;45(4):429-35.
2004: Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Annals of hematology 2004;83(3):176-82.
2004: Eich Hans Theodor; Staar Susanne; Gossmann Axel; Hansemann Katja; Skripnitchenko Roman; Kocher Martin; Semrau Robert; Engert Andreas; Josting Andreas; Franklin Jeremy; Krug Barbara; Diehl Volker; Müller Rolf-Peter;
Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.
International journal of radiation oncology, biology, physics 2004;58(4):1121-7.
2004: Scheid Christof; Hermann Karin; Kremer Gisela; Holsing Anja; Heck Georg; Fuchs Michael; Waldschmidt Dirk; Herrmann Hans-Joachim; Söhngen Dietmar; Diehl Volker; Schwenk Achim
Randomized, double-blind, controlled study of glycyl-glutamine-dipeptide in the parenteral nutrition of patients with acute leukemia undergoing intensive chemotherapy.
Nutrition (Burbank, Los Angeles County, Calif.) 2004;20(3):249-54.
2004: Eich Hans Theodor; Müller Rolf-Peter; Schneeweiss Angelika; Hansemann Katja; Semrau Robert; Willich Normann; Rübe Christian; Sehlen Susanne; Hinkelbein Margit; Diehl Volker
Initiation of a teleradiotherapeutic network for patients in German lymphoma studies.
International journal of radiation oncology, biology, physics 2004;58(3):805-8.
2004: Cornely Oliver A; Wicke Thomas; Seifert Harald; Bethe Ullrich; Schwonzen Martin; Reichert Dietmar; Ullmann Andrew J; Karthaus Meinolf; Breuer Kai; Salzberger Bernd; Diehl Volker; Fätkenheuer Gerd
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
International journal of hematology 2004;79(1):74-8.
2004: Josting A; Behringer K; Engert A; Diehl V
[Modern pharmacotherapy of Hodgkin disease]
Der Internist 2004;45(1):93-101.
2004: Thiele J; Kvasnicka H M; Schmitt-Gräff A; Hülsemann R; Diehl V
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Histology and histopathology 2004;19(1):239-50.
2004: Diehl Volker; Thomas Roman K; Re Daniel
Part II: Hodgkin's lymphoma--diagnosis and treatment.
The lancet oncology 2004;5(1):19-26.
2004: Thomas Roman K; Re Daniel; Wolf Jürgen; Diehl Volker
Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells.
The lancet oncology 2004;5(1):11-8.
2003: Thomas Roman K; Diehl Volker
Unhappy neighbourhood: spatial genome organisation and lymphomagenesis in B cells.
Lancet 2003;362(9399):1868-70.
2003: Pfistner B; Mehl C; Klöss M; Löffler M; Herrmann-Frank A; Diehl V
[Quality standards and their assurance for study centers in the competence network malignant lymphoma]
Klinische Pädiatrie 2003;215(6):341-4.
2003: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Diehl V
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Histopathology 2003;43(5):470-9.
2003: Borchmann Peter; Treml John F; Hansen Hinrich; Gottstein Claudia; Schnell Roland; Staak Oliver; Zhang Hui-fen; Davis Thomas; Keler Tibor; Diehl Volker; Graziano Robert F; Engert Andreas
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Blood 2003;102(10):3737-42.
2003: Rüffer J U; Flechtner H; Tralls P; Josting A; Sieber M; Lathan B; Diehl V;
Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG).
European journal of cancer (Oxford, England : 1990) 2003;39(15):2179-86.
2003: Hartmann P; Rehwald U; Salzberger B; Franzen C; Sieber M; Wöhrmann A; Diehl V
BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(10):1562-9.
2003: Engert Andreas; Schiller Petra; Josting Andreas; Herrmann Richard; Koch Peter; Sieber Markus; Boissevain Friederike; De Wit Maike; Mezger Jorg; Duhmke Eckhart; Willich Normann; Muller Rolf-Peter; Schmidt Bernhard F; Renner Helmut; Muller-Hermelink Hans Konrad; Pfistner Beate; Wolf Jurgen; Hasenclever Dirk; Loffler Markus; Diehl Volker;
Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3601-8.
2003: Glossmann Jan-Peter; Staak Jan Oliver; Wickenhauser Claudia; Diehl Volker; Josting Andreas
Extramedullary acute myeloid leukemia (granulocytic sarcoma) with arm paresis, maculopapular exanthema and organ involvement.
Leukemia & lymphoma 2003;44(9):1619-21.
2003: Staak Jan Oliver; Glossmann Jan-Peter; Esser Johannes Markus; Diehl Volker; Mietz Holger; Josting Andreas
Thalidomide for systemic capillary leak syndrome.
The American journal of medicine 2003;115(4):332-4.
2003: Heuser Claudia; Diehl Volker; Abken Hinrich; Hombach Andreas
Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
International journal of cancer. Journal international du cancer 2003;106(4):545-52.
2003: Josting Andreas; Wiedenmann Sabine; Franklin Jeremy; May Michael; Sieber Markus; Wolf Juergen; Engert Andreas; Diehl Volker;
Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3440-6.
2003: Josting Andreas; Diehl Volker
Current treatment strategies in early stage Hodgkin's disease.
Current treatment options in oncology 2003;4(4):297-305.
2003: Glossmann J-P; Engert A; Wassmer G; Flechtner H; Ko Y; Rudolph C; Metzner B; Dörken B; Wiedenmann S; Diehl V; Josting A
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial.
Annals of hematology 2003;82(8):469-75.
2003: Rueffer U; Sieber M; Stemberg M; Gossmann A; Josting A; Koch T; Grotenhermen F; Diehl V;
Spleen involvement in Hodgkin's lymphoma: assessment and risk profile.
Annals of hematology 2003;82(7):390-6.
2003: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Diehl V
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Leukemia & lymphoma 2003;44(6):949-53.
2003: Diehl Volker; Franklin Jeremy; Pfreundschuh Michael; Lathan Bernd; Paulus Ursula; Hasenclever Dirk; Tesch Hans; Herrmann Richard; Dörken Bernd; Müller-Hermelink Hans-Konrad; Dühmke Eckhardt; Loeffler Markus;
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
The New England journal of medicine 2003;348(24):2386-95.
2003: Re Daniel; Starostik Petr; Massoudi Nadia; Staratschek-Jox Andrea; Dries Volker; Thomas Roman K; Diehl Volker; Wolf Jürgen
Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells.
Cancer research 2003;63(10):2606-9.
2003: Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink H K; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1734-9.
2003: von Wasielewski Sabine; Franklin Jeremy; Fischer Robert; Hübner Klaus; Hansmann Martin L; Diehl Volker; Georgii Axel; von Wasielewski Reinhard
Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages.
Blood 2003;101(10):4063-9.
2003: Schwering Ines; Bräuninger Andreas; Distler Verena; Jesdinsky Julia; Diehl Volker; Hansmann Martin-Leo; Rajewsky Klaus; Küppers Ralf
Profiling of Hodgkin's lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin's lymphoma-specific genes.
Molecular medicine (Cambridge, Mass.) 2003;9(3-4):85-95.
2003: Staak J O; Dietlein M; Engert A; Weihrauch M R; Schomäcker K; Fischer Th; Eschner W; Borchmann P; Diehl V; Schicha H; Schnell R
[Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects]
Nuklearmedizin. Nuclear medicine 2003;42(1):19-24.
2003: Schwering Ines; Bräuninger Andreas; Klein Ulf; Jungnickel Berit; Tinguely Marianne; Diehl Volker; Hansmann Martin-Leo; Dalla-Favera Riccardo; Rajewsky Klaus; Küppers Ralf
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
Blood 2003;101(4):1505-12.
2003: Weihrauch Martin R; Dietlein Markus; Schicha Harald; Diehl Volker; Tesch Hans
Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma.
Leukemia & lymphoma 2003;44(1):15-22.
2003: Rehwald Ute; Schulz Holger; Reiser Marcel; Sieber Markus; Staak Jan Oliver; Morschhauser Franck; Driessen Christoph; Rudiger Thomas; Muller-Hermelink Konrad; Diehl Volker; Engert Andreas;
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
Blood 2003;101(2):420-4.
2003: Eich Hans Theodor; Müller Rolf-Peter M; Ansén Sascha; Josting Andreas; Engert Andreas; Hansemann Katja; Pfistner Beate; Wolf Jürgen; Willich Normann; Diehl Volker
[New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology]
Röntgenpraxis; Zeitschrift für radiologische Technik 2003;55(3):114-24.
2003: Diehl Volker; Stein Harald; Hummel Michael; Zollinger Raphael; Connors Joseph M
Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():225-47.
2003: Kvasnicka Hans Michael; Thiele Juergen; Schmitt-Graeff Annette; Diehl Volker; Niederle Norbert; Schaefer Hans Eckart
Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
Acta haematologica 2003;109(1):53-6.
2002: Ansén S; Sieber M; Wingbermühle K; Josting A; Diehl V
[Current therapeutic strategies in Hodgkin lymphoma]
Der Internist 2002;43(12):1544-50.
2002: Wilde S; Jetter A; Zaigier M; Rietbrock S; Menzel H; Sieber M; Tesch H; Hempel G; Busse D; Schwab M; Reif S; Jaehde U; Diehl V; Fuhr U
Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.
International journal of clinical pharmacology and therapeutics 2002;40(12):586-8.
2002: Vockerodt Martina; Belge Gazanfer; Kube Dieter; Irsch Johannes; Siebert Reiner; Tesch Hans; Diehl Volker; Wolf Jürgen; Bullerdiek Jörn; Staratschek-Jox Andrea
An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591.
British journal of haematology 2002;119(3):640-6.
2002: Krause Anke S; Weihrauch Martin R; Bode Udo; Fleischhack Gudrun; Elter Thomas; Heuer Theodor; Engert Andreas; Diehl Volker; Josting Andreas
Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Leukemia & lymphoma 2002;43(11):2139-43.
2002: Weihrauch Martin R; Skibowski Edmund; Koslowsky Thomas C; Voiss Wilfried; Re Daniel; Kuhn-Regnier Ferdinand; Bannwarth Carolin; Siedek Michel; Diehl Volker; Bohlen Heribert
Immunomagnetic enrichment and detection of micrometastases in colorectal cancer: correlation with established clinical parameters.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(21):4338-43.
2002: Schulz Holger; Klein Saskia Karina; Rehwald Ute; Reiser Marcel; Hinke Axel; Knauf Wolfgang-Ulrich; Aulitzky Walter-Erich; Hensel Manfred; Herold Michael; Huhn Dieter; Hallek Michael; Diehl Volker; Engert Andreas;
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Blood 2002;100(9):3115-20.
2002: Borchmann Peter; Schnell Roland; Fuss Irene; Manzke Oliver; Davis Thomas; Lewis Lionel D; Behnke Detlev; Wickenhauser Claudia; Schiller Petra; Diehl Volker; Engert Andreas
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
Blood 2002;100(9):3101-7.
2002: Staak Jan Oliver; Glossmann Jan-Peter; Diehl Volker; Josting Andreas
[Hepatitis-C-virus-associated cryoglobulinemia. Pathogenesis, diagnosis and treatment]
Medizinische Klinik (Munich, Germany : 1983) 2002;97(10):601-8.
2002: Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner H H; Dörken B; Hossfeld D K; Diehl V; Engert A;
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(10):1628-35.
2002: Chemnitz Jens; Draube Andreas; Scheid Christof; Staib Peter; Schulz Armin; Diehl Volker; Söhngen Dietmar
Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.
American journal of hematology 2002;71(2):105-8.
2002: Thiele Juergen; Kvasnicka Hans Michael; Schmitt-Graeff Annette; Zankovich Rudolph; Diehl Volker
Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients.
American journal of hematology 2002;70(4):283-91.
2002: Glossmann Jan-Peter; Josting Andreas; Diehl Volker
New treatments for Hodgkin's disease.
Current treatment options in oncology 2002;3(4):283-90.
2002: Schmitz Norbert; Pfistner Beate; Sextro Michael; Sieber Markus; Carella Angelo M; Haenel Matthias; Boissevain Friederike; Zschaber Reinhart; Müller Peter; Kirchner Hartmut; Lohri Andreas; Decker Susanne; Koch Bettina; Hasenclever Dirk; Goldstone Anthony H; Diehl Volker;
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Lancet 2002;359(9323):2065-71.
2002: Voliotis Dimitris; Diehl Volker
Challenges in treating hematologic malignancies.
Seminars in oncology 2002;29(3 Suppl 8):30-9.
2002: Schnell Roland; Staak Oliver; Borchmann Peter; Schwartz Christine; Matthey Bärbel; Hansen Hinrich; Schindler John; Ghetie Victor; Vitetta Ellen S; Diehl Volker; Engert Andreas
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1779-86.
2002: Thiele J; Kvasnicka H M; Zankovich R; Diehl V
Early-stage idiopathic (primary) myelofibrosis--current issues of diagnostic features.
Leukemia & lymphoma 2002;43(5):1035-41.
2002: Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Annals of hematology 2002;81(5):258-66.
2002: Reiser M; Josting A; Soltani M; Staib P; Salzberger B; Diehl V; Engert A
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
Leukemia & lymphoma 2002;43(4):805-11.
2002: Walshe R; Herrmann-Frank A; Diehl V
[Center of excellence, cancer center, competence network: confusion of terminology?]
Deutsche medizinische Wochenschrift (1946) 2002;127(17):913-4.
2002: Re D; Wickenhauser C; Ahmadi T; Buchdunger E; Kochanek M; Diehl V; Wolf J
Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease.
British journal of cancer 2002;86(8):1333-5.
2002: Thomas Roman Kurt; Kallenborn Anne; Wickenhauser Claudia; Schultze Joachim Ludwig; Draube Andreas; Vockerodt Martina; Re Daniel; Diehl Volker; Wolf Jürgen
Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells.
The American journal of pathology 2002;160(4):1521-8.
2002: Weihrauch M R; Re D; Bischoff S; Dietlein M; Scheidhauer K; Krug B; Textoris F; Ansén S; Franklin J; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.
Annals of hematology 2002;81(1):20-5.
2002: Sieber Markus; Tesch Hans; Pfistner Beate; Rueffer Ulrich; Lathan Bernd; Brosteanu Oana; Paulus Ursula; Koch Tina; Pfreundschuh Michael; Loeffler Markus; Engert Andreas; Josting Andreas; Wolf Jürgen; Hasenclever Dirk; Franklin Jeremy; Duehmke Eckhart; Georgii Axel; Schalk Klaus-Peter; Kirchner Hartmut; Doelken Gottfried; Munker Reinhold; Koch Peter; Herrmann Richard; Greil Richard; Anselmo Anna Paola; Diehl Volker
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):476-84.
2002: Re Daniel; Benenson Lena; Wickenhauser Claudia; Starostik Petr; Staratschek-Jox Andrea; Müller-Hermelink Hans Konrad; Diehl Volker; Wolf Jürgen
Proficient mismatch repair protein expression in Hodgkin and Reed Sternberg cells.
International journal of cancer. Journal international du cancer 2002;97(2):205-10.
2002: Josting Andreas; Franklin Jeremy; May Michael; Koch Peter; Beykirch Maria K; Heinz Juergen; Rudolph Christian; Diehl Volker; Engert Andreas
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):221-30.
2002: Weihrauch Martin R; Skibowski Edmund; Draube Andreas; Geller Andrea; Tesch Hans; Diehl Volker; Bohlen Heribert
Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies.
Clinical & experimental metastasis 2002;19(7):617-21.
2002: Thomas R K; Re D; Zander T; Wolf J; Diehl V
Epidemiology and etiology of Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 4():147-52.
2002: Franklin J; Diehl V
Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():98-101.
2002: Carde P; Koscielny S; Franklin J; Axdorph U; Raemaekers J; Diehl V; Aleman B; Brosteanu O; Hasenclever D; Oberlin O; Bonvin N; Björkholm M
Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():86-91.
2002: Re D; Zander T; Diehl V; Wolf J
Genetic instability in Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():19-22.
2002: Josting A; Raemakers J M; Diehl V; Engert A
New concepts for relapsed Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():117-21.
2002: Josting A; Engert A; Diehl V; Canellos G P
Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():112-6.
2002: Wiedenmann S; Wolf J; Diehl V
An overview of the Fifth International Symposium on Hodgkin's lymphoma: recent advances in basic and clinical research.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13 Suppl 1():1-3.
2001: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Goekce D; Diehl V; Zankovich R; Schaefer H E
Therapy-related changes of CD34+ progenitor cells in chronic myeloid leukemia: a morphometric study on sequential trephine biopsies.
Journal of hematotherapy & stem cell research 2001;10(6):827-36.
2001: Weihrauch M R; Diehl V; Bohlen H
[Artificial sweeteners--are they potentially carcinogenic?]
Medizinische Klinik (Munich, Germany : 1983) 2001;96(11):670-5.
2001: Kornacker M; Schlattner U; Wallimann T; Verneris M R; Negrin R S; Kornacker B; Staratschek-Jox A; Diehl V; Wolf J
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis.
International journal of cancer. Journal international du cancer 2001;94(4):513-9.
2001: Re D; Staratschek-Jox A; Holtick U; Diehl V; Wolf J
Deregulation of immunoglobulin gene transcription in the Hodgkin-Reed Sternberg cell line L1236.
British journal of haematology 2001;115(2):326-8.
2001: Weihrauch M R; Re D; Scheidhauer K; Ansén S; Dietlein M; Bischoff S; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Blood 2001;98(10):2930-4.
2001: Rueffer U; Breuer K; Josting A; Lathan B; Sieber M; Manzke O; Grotenhermen F J; Tesch H; Bredenfeld H; Koch P; Nisters-Backes H; Wolf J; Engert A; Diehl V
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1307-11.
2001: Weihrauch M R; Rabe K; Kochanek M; Tesch H; Diehl V; Wolf J
[Factitious disorders. Hematologic, neurologic and dermatologic symptoms in a physician with factitious disorder]
Medizinische Klinik (Munich, Germany : 1983) 2001;96(9):555-60.
2001: Kube D; Holtick U; Vockerodt M; Ahmadi T; Haier B; Behrmann I; Heinrich P C; Diehl V; Tesch H
STAT3 is constitutively activated in Hodgkin cell lines.
Blood 2001;98(3):762-70.
2001: Reiser M; Bredenfeld H; Engert A; Diehl V
The role of ifosfamide in the treatment of relapsed and refractory lymphoma.
European journal of haematology. Supplementum 2001;64():37-40.
2001: Chemnitz J; Schulz A; Diehl V; Söhngen D
[Thrombotic-thrombocytopenic purpura (Moschcowitz syndrome)]
Medizinische Klinik (Munich, Germany : 1983) 2001;96(6):343-50.
2001: Rubbert A; Diehl V
[New approaches to treatment in immunology with monoclonal antibodies]
Der Internist 2001;42(6):843, 846-53.
2001: Schnell R; Hiddemann W; Diehl V; Engert A
[Clinical use of monoclonal antibodies in malignant lymphomas]
Der Internist 2001;42(6):815-6, 819-26.
2001: Engert A; Diehl V
[Therapy with monoclonal antibodies]
Der Internist 2001;42(6):801-2.
2001: Kvasnicka H M; Thiele J; Schmitt-Graeff A; Diehl V; Zankovich R; Niederle N; Leder L D; Schaefer H E
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):2994-3009.
2001: Dühmke E; Franklin J; Pfreundschuh M; Sehlen S; Willich N; Rühl U; Müller R P; Lukas P; Atzinger A; Paulus U; Lathan B; Rüffer U; Sieber M; Wolf J; Engert A; Georgii A; Staar S; Herrmann R; Beykirch M; Kirchner H; Emminger A; Greil R; Fritsch E; Koch P; Drochtert A; Brosteanu O; Hasenclever D; Loeffler M; Diehl V
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(11):2905-14.
2001: Irsch J; Wolf J; Tesch H; Diehl V; Radbruch A; Staratschek-Jox A
Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease-derived cell lines.
British journal of haematology 2001;113(3):785-93.
2001: Borchmann P; Schnell R; Knippertz R; Staak J O; Camboni G M; Bernareggi A; Hübel K; Staib P; Schulz A; Diehl V; Engert A
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(5):661-7.
2001: Re D; Benenson E; Beyer M; Gresch O; Draube A; Diehl V; Wolf J
Cell fusion is not involved in the generation of giant cells in the Hodgkin-Reed Sternberg cell line L1236.
American journal of hematology 2001;67(1):6-9.
2001: Pfreundschuh M; Hasenclever D; Loeffler M; Ehninger G; Schmitz N; Kirchner H; Koch P; Lathan B; Rueffer U; Sextro M; Franklin J; Tesch H; Diehl V;
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(4):471-7.
2001: Thiele J; Kvasnicka H M; Zankovich R; Diehl V
The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
Haematologica 2001;86(4):368-74.
2001: Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2026-32.
2001: Thiele J; Kvasnicka H M; Zankovich R; Diehl V
Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis.
Annals of hematology 2001;80(3):160-5.
2001: Re D; Müschen M; Ahmadi T; Wickenhauser C; Staratschek-Jox A; Holtick U; Diehl V; Wolf J
Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.
Cancer research 2001;61(5):2080-4.
2001: Kvasnicka H M; Thiele J; Schmitt-Graeff A; Diehl V; Zankovich R; Niederle N; Leder L D; Schaefer H E
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
British journal of haematology 2001;112(3):727-39.
2001: Ansén S; Engert A; Wolf J; Sieber M; Paulus U; Diehl V
[German Hodgkin's Lymphoma Study Group]
Onkologie 2001;24 Suppl 1():35-48.
2001: Draube A; Pfister R; Vockerodt M; Schuster S; Kube D; Diehl V; Tesch H
Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement.
Annals of hematology 2001;80(2):83-9.
2001: Cornely O A; Bethe U; Salzberger B; Franzen C; Hartmann P; Steinmetz T; Fätkenheuer G; Seifert H; Diehl V; Schrappe M
Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever.
Annals of hematology 2001;80(2):103-8.
2001: Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
International journal of cancer. Journal international du cancer 2001;91(4):516-22.
2001: Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
International journal of cancer. Journal international du cancer 2001;91(4):508-15.
2001: Staratschek-Jox A; Thomas R K; Zander T; Massoudi N; Kornacker M; Bullerdiek J; Fonatsch C; Diehl V; Wolf J
Loss of heterozygosity in the Hodgkin-Reed Sternberg cell line L1236.
British journal of cancer 2001;84(3):381-7.
2001: Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Medical and pediatric oncology 2001;36(1):185-9.
2001: Cornely O A; Chemnitz J; Brochhagen H G; Lemmer K; Schütt H; Söhngen D; Staib P; Wickenhauser C; Diehl V; Tintelnot K
Disseminated Neocosmospora vasinfecta infection in a patient with acute nonlymphocytic leukemia.
Emerging infectious diseases 2001;7(1):149-52.
2001: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Diehl V; Niederle N; Schaefer H E
Bone marrow histopathology predicting blast crisis in chronic myeloid leukemia.
Acta haematologica 2001;105(4):244-6.
2001: Thiele J; Kvasnicka H M; Muehlhausen K; Walter S; Zankovich R; Diehl V
Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients.
Pathology, research and practice 2001;197(2):77-84.
2000: Müschen M; Re D; Jungnickel B; Diehl V; Rajewsky K; Küppers R
Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction.
The Journal of experimental medicine 2000;192(12):1833-40.
2000: Hübel K; Mansmann G; Schäfer H; Oberhäuser F; Diehl V; Engert A
Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.
Cytokine 2000;12(12):1797-800.
2000: Thiele J; Kvasnicka H M; Zankovich R; Diehl V
Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Haematologica 2000;85(11):1126-34.
2000: Müschen M; Re D; Bräuninger A; Wolf J; Hansmann M L; Diehl V; Küppers R; Rajewsky K
Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.
Cancer research 2000;60(20):5640-3.
2000: Hombach A; Schneider C; Sent D; Koch D; Willemsen R A; Diehl V; Kruis W; Bolhuis R L; Pohl C; Abken H
An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
International journal of cancer. Journal international du cancer 2000;88(1):115-20.
2000: Diehl V; Schütt I; Walshe R
[Publisher fraud. The publication of falsified medical research results]
Deutsche medizinische Wochenschrift (1946) 2000;125(38):1112-4.
2000: Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1105-14.
2000: Chemnitz J; Fuchs M; Blau W; Hartmann P; Wickenhauser C; Scheid C; Schulz A; Diehl V; Söhngen D
Fatal thrombotic thrombocytopenic purpura as a rare complication following allogeneic stem cell transplantation.
Annals of hematology 2000;79(9):527-9.
2000: Anagnostopoulos I; Hansmann M L; Franssila K; Harris M; Harris N L; Jaffe E S; Han J; van Krieken J M; Poppema S; Marafioti T; Franklin J; Sextro M; Diehl V; Stein H
European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.
Blood 2000;96(5):1889-99.
2000: Müller A; Bialek R; Fätkenheuer G; Salzberger B; Diehl V; Franzen C
Detection of Isospora belli by polymerase chain reaction using primers based on small-subunit ribosomal RNA sequences.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2000;19(8):631-4.
2000: Glossmann J P; Schliebusch O; Diehl V; Walshe R
["Lean management" in hospitals: potentials and limitations]
Medizinische Klinik (Munich, Germany : 1983) 2000;95(8):470-3.
2000: Benedek D; Kiehl M; Draube A; Chemnitz J; Diehl V; Söhngen D
Atypical chronic myeloid leukaemia with trisomy 21 mosaicism as a sole chromosomal abnormality.
Leukemia & lymphoma 2000;38(5-6):639-44.
2000: Franzen C; Müller A; Bialek R; Diehl V; Salzberger B; Fätkenheuer G
Taxonomic position of the human intestinal protozoan parasite Isospora belli as based on ribosomal RNA sequences.
Parasitology research 2000;86(8):669-76.
2000: Josting A; Rueffer U; Franklin J; Sieber M; Diehl V; Engert A
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.
Blood 2000;96(4):1280-6.
2000: Röhrig G; Kilter H; Beuckelmann D; Kröner A; Scheid C; Diehl V; Söhngen D
Congenital dyserythropoietic anemia type III associated with congenital atrioseptal defect has led to severe cardiac problems in a 32-year-old patient.
American journal of hematology 2000;64(4):314-6.
2000: Breuer K; Diehl V; Rüffer U
[Long-term toxic sequelae of the treatment of Hodgkin's disease]
Medizinische Klinik (Munich, Germany : 1983) 2000;95(7):378-84.
2000: Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra H S; Benoehr C; Pacini M; Bonadonna G; Diehl V
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(13):2615-9.
2000: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer H E
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
American journal of clinical pathology 2000;114(1):57-65.
2000: Fätkenheuer G; Hell K; Roers A; Diehl V; Salzberger B
Spontaneous regression of HIV associated T-cell non-Hodgkin's lymphoma with highly active antiretroviral therapy.
European journal of medical research 2000;5(6):236-40.
2000: Hombach A; Heuser C; Gerken M; Fischer B; Lewalter K; Diehl V; Pohl C; Abken H
T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.
Gene therapy 2000;7(12):1067-75.
2000: Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Blood 2000;95(12):3909-14.
2000: Barth S; Huhn M; Matthey B; Schnell R; Tawadros S; Schinköthe T; Lorenzen J; Diehl V; Engert A
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
International journal of cancer. Journal international du cancer 2000;86(5):718-24.
2000: Tesch H; Engert A; Manzke O; Diehl V; Bohlen H
Treatment of patients with malignant lymphomas with monoclonal antibodies.
Bone marrow transplantation 2000;25 Suppl 2():S50-3.
2000: Müller A; Franzen C; Klussmann P; Wagner M; Diehl V; Fätkenheuer G; Salzberger B; Ablashi D V; Krueger G R
Human herpesvirus type 8 in HIV-infected patients with interstitial pneumonitis.
The Journal of infection 2000;40(3):242-7.
2000: Franklin J; Paulus U; Lieberz D; Breuer K; Tesch H; Diehl V
Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):617-23.
2000: Re D; Benenson E; Wolf J; Diehl V; Staratschek-Jox A
Lack of BCL10 mutations in Hodgkin's disease-derived cell lines.
British journal of haematology 2000;109(2):420-2.
2000: Mantovani L; Lentini G; Hentschel B; Wickramanayake P D; Loeffler M; Diehl V; Tesch H
Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
British journal of haematology 2000;109(2):367-75.
2000: Mücke S; Draube A; Polack A; Pawlita M; Massoudi N; Staratschek-Jox A; Bohlen H; Bornkamm G; Diehl V; Wolf J
Suppression of the tumorigenic growth of Burkitt's lymphoma cells in immunodeficient mice by cytokine gene transfer using EBV-derived episomal expression vectors.
International journal of cancer. Journal international du cancer 2000;86(3):301-6.
2000: Walshe R; Waldschmidt D; Diehl V
[True medicine? Economic analysis and perspectives for medical service]
Der Unfallchirurg 2000;103(4):334-40.
2000: Pfitzner T; Engert A; Wittor H; Schinköthe T; Oberhäuser F; Schulz H; Diehl V; Barth S
A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(4):754-66.
2000: Schäfer H; Hübel K; Bohlen H; Mansmann G; Hegener K; Richarz B; Oberhäuser F; Wassmer G; Hölscher A H; Pichlmaier H; Diehl V; Engert A
Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy.
Annals of hematology 2000;79(3):143-51.
2000: Bohlen H; Kessler M; Sextro M; Diehl V; Tesch H
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease.
Annals of hematology 2000;79(3):110-3.
2000: Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
British journal of haematology 2000;108(4):805-16.
2000: Josting A; Reiser M; Wickramanayake P D; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Leukemia & lymphoma 2000;37(1-2):185-7.
2000: Josting A; Reiser M; Wickramanayake P D; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Leukemia & lymphoma 2000;37(1-2):115-23.
2000: Re D; Hofmann A; Wolf J; Diehl V; Staratschek-Jox A
Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.
Experimental hematology 2000;28(3):348.
2000: Re D; Schwenk A; Hegener P; Bamborschke S; Diehl V; Tesch H
Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(2):217-20.
2000: Lieberz D; Sextro M; Paulus U; Franklin J; Tesch H; Diehl V
How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of hematology 2000;79(2):73-8.
2000: Chemnitz J M; Schulz A; Salameh A; Scheid C; Müller R; Draube A; Diehl V; Söhngen D
[Thrombotic thrombocytopenic purpura (Moschkowitz-syndrome) caused by ticlopidine]
Medizinische Klinik (Munich, Germany : 1983) 2000;95(2):96-100.
2000: Schwenk A; Schlottmann S; Kremer G; Diehl V; Salzberger B; Ward L
Fever and sepsis during neutropenia are associated with expansion of extracellular and loss of intracellular water.
Clinical nutrition (Edinburgh, Scotland) 2000;19(1):35-41.
2000: von Wasielewski R; Seth S; Franklin J; Fischer R; Hübner K; Hansmann M L; Diehl V; Georgii A
Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.
Blood 2000;95(4):1207-13.
2000: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Zirbes T K; Birnbaum F; Kressmann C; Melguizo-Grahmann M; Frackenpohl H; Sprungmann C; Leder L D; Diehl V; Zankovich R; Schaefer H E; Niederle N; Fischer R
Bone marrow features and clinical findings in chronic myeloid leukemia--a comparative, multicenter, immunohistological and morphometric study on 614 patients.
Leukemia & lymphoma 2000;36(3-4):295-308.
2000: Müller A; Trammer T; Chioralia G; Seitz H M; Diehl V; Franzen C
Ribosomal RNA of Nosema algerae and phylogenetic relationship to other microsporidia.
Parasitology research 2000;86(1):18-23.
2000: Re D; Hofmann A; Wolf J; Diehl V; Staratschek-Jox A
Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95.
Experimental hematology 2000;28(1):31-5.
2000: Thiele J; Kvasnicka H M; Schmitt-Graeff A; Spohr M; Diehl V; Zankovich R; Niederle N; Leder L D
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
British journal of haematology 2000;108(1):64-71.
2000: Schnell R; Vitetta E; Schindler J; Borchmann P; Barth S; Ghetie V; Hell K; Drillich S; Diehl V; Engert A
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(1):129-35.
2000: Jungnickel B; Staratschek-Jox A; Bräuninger A; Spieker T; Wolf J; Diehl V; Hansmann M L; Rajewsky K; Küppers R
Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.
The Journal of experimental medicine 2000;191(2):395-402.
2000: Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):332-9.
2000: Staratschek-Jox A; Kotkowski S; Belge G; Rüdiger T; Bullerdiek J; Diehl V; Wolf J
Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease.
The American journal of pathology 2000;156(1):209-16.
2000: Pfistner B; Paulus U; Glossmann J P; Walshe R; Tesch H; Diehl V;
Can factors influencing in-patient treatment in Hodgkin's disease be identified?--Retrospective analysis of HD6 patients of the GHSG.
Studies in health technology and informatics 2000;77():399-403.
2000: Cornely O A; Salzberger B; Bethe U; Seifert H; Fätkenheuer G; Diehl V; Schrappe M
Ceftriaxone and cefotaxime are equally effective in the treatment of neutropenic fever.
Antibiotics and chemotherapy 2000;50():37-46.
1999: Rueffer U; Sieber M; Josting A; Breuer K; Grotenhermen F J; Bredenfeld H; Tesch H; Nisters-Backes H; Engert A; Diehl V
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1343-8.
1999: Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
European journal of medical research 1999;4(11):449-55.
1999: Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):473-80.
1999: Thiele J; Kvasnicka H M; Boeltken B; Zankovich R; Diehl V; Fischer R
Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1999;13(11):1741-8.
1999: Schwenk A; Beisenherz A; Kremer G; Diehl V; Salzberger B; Fätkenheuer G
Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment.
The American journal of clinical nutrition 1999;70(5):867-73.
1999: Schiefer D; Gottstein C; Diehl V; Engert A
[Anti-angiogenesis: a new approach to tumor therapy?]
Medizinische Klinik (Munich, Germany : 1983) 1999;94(10):570-9.
1999: Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Blood 1999;94(7):2217-24.
1999: Steinmetz H T; Schulz A; Staib P; Scheid C; Glasmacher A; Neufang A; Franklin J; Tesch H; Diehl V; Dias Wickramanayake P
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.
Annals of hematology 1999;78(9):418-25.
1999: Wickenhauser C; Borchmann P; Diehl V; Scharffetter-Kochanek K
Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphoma.
Leukemia & lymphoma 1999;35(1-2):201-6.
1999: Jütte A; Schwenk A; Franzen C; Römer K; Diet F; Diehl V; Fätkenheuer G; Salzberger B
Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?
AIDS (London, England) 1999;13(13):1796-7.
1999: Chemnitz J; Wolter S; Bohrer M H; Brochhagen G; de Lacroix W F; Söhngen D; Diehl V; Wolf J
[Massive chronic diarrhea. 56-year-old patient with sarcoidosis and high grade pleomorphic T-cell non-Hodgkin lymphoma]
Der Internist 1999;40(9):969-73.
1999: Engert A; Josting A; Reiser M; Söhngen D; Diehl V
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology]
Medizinische Klinik (Munich, Germany : 1983) 1999;94(8):431-42.
1999: Fätkenheuer G; Hoetelmans R M; Hunn N; Schwenk A; Franzen C; Reiser M; Jütte A; Rockstroh J; Diehl V; Salzberger B
Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.
AIDS (London, England) 1999;13(12):1485-9.
1999: Kornacker M; Jox A; Vockerodt M; Tesch H; Bohlen H; Diehl V; Wolf J
Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin's disease.
British journal of haematology 1999;106(2):528-31.
1999: Manzke O; Fitzgerald K J; Holliger P; Klock J; Span M; Fleischmann B; Hescheler J; Qinghua L; Johnson K S; Diehl V; Hoogenboom H R; Bohlen H
CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors.
International journal of cancer. Journal international du cancer 1999;82(5):700-8.
1999: Barth S; Matthey B; Huhn M; Diehl V; Engert A
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Cytokines, cellular & molecular therapy 1999;5(2):69-78.
1999: Jox A; Sieber M; Wolf J; Diehl V
Hodgkin's disease - new treatment strategies toward the cure of patients.
Cancer treatment reviews 1999;25(3):169-76.
1999: Reiser M; Josting A; Draube A; Mapara M Y; Scheid C; Chemnitz J; Tesch H; Wolf J; Diehl V; Söhngen D; Engert A
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization.
Bone marrow transplantation 1999;23(12):1223-8.
1999: Scheid C; Draube A; Reiser M; Schulz A; Chemnitz J; Nelles S; Fuchs M; Winter S; Wickramanayake P D; Diehl V; Söhngen D
Using at least 5x10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation.
Bone marrow transplantation 1999;23(11):1177-81.
1999: Schwenk A; Kremer G; Cornely O; Diehl V; Fätkenheuer G; Salzberger B
Body weight changes with protease inhibitor treatment in undernourished HIV-infected patients.
Nutrition (Burbank, Los Angeles County, Calif.) 1999;15(6):453-7.
1999: Klimka A; Barth S; Matthey B; Roovers R C; Lemke H; Hansen H; Arends J W; Diehl V; Hoogenboom H R; Engert A
An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
British journal of cancer 1999;80(8):1214-22.
1999: Jox A; Zander T; Küppers R; Irsch J; Kanzler H; Kornacker M; Bohlen H; Diehl V; Wolf J
Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells.
Blood 1999;93(11):3964-72.
1999: Greil R; Holzner B; Kemmler G; Kopp M; Buchowski A; Oberaigner W; Fritsch E; Dirnhofer S; Rueffer U; Diehl V; Sperner-Unterweger B
Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994.
European journal of cancer (Oxford, England : 1990) 1999;35(5):698-706.
1999: Engert A; Höffken K; Freund M; Diehl V
[Hematology and internal medicine oncology]
Der Internist 1999;40(4):356-68.
1999: Diet F; Hartmann P; Lang A; Fätkenheuer G; Diehl V; Erdmann E
[Meningococcal sepsis in 3 young men]
Deutsche medizinische Wochenschrift (1946) 1999;124(14):424-8.
1999: Reiser M; Josting A; Dias Wickramanayake P; Draube A; Scheid C; Tesch H; Wolf J; Diehl V; Engert A
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1999;33(3-4):305-12.
1999: Thiele J; Kvasnicka H M; Diehl V; Fischer R; Michiels J
Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.
Leukemia & lymphoma 1999;33(3-4):207-18.
1999: Matthey B; Engert A; Klimka A; Diehl V; Barth S
A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins.
Gene 1999;229(1-2):145-53.
1999: Diehl V; Sextro M; Franklin J; Hansmann M L; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):776-83.
1999: Müller A; Stellermann K; Hartmann P; Schrappe M; Fätkenheuer G; Salzberger B; Diehl V; Franzen C
A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens.
Clinical and diagnostic laboratory immunology 1999;6(2):243-6.
1999: Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
International journal of cancer. Journal international du cancer 1999;80(5):715-22.
1999: Hombach A; Koch D; Sircar R; Heuser C; Diehl V; Kruis W; Pohl C; Abken H
A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.
Gene therapy 1999;6(2):300-4.
1999: Liu Q H; Bohlen H; Titzer S; Christensen O; Diehl V; Hescheler J; Fleischmann B K
Expression and a role of functionally coupled P2Y receptors in human dendritic cells.
FEBS letters 1999;445(2-3):402-8.
1999: Hübel K; Hegener K; Schnell R; Mansmann G; Oberhäuser F; Staib P; Diehl V; Engert A
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Annals of hematology 1999;78(2):73-7.
1999: Kvasnicka H M; Thiele J; Regn C; Zankovich R; Diehl V; Fischer R
Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis.
Annals of hematology 1999;78(2):65-72.
1999: Re D; Bamborschke S; Feiden W; Schröder R; Lehrke R; Diehl V; Tesch H
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Bone marrow transplantation 1999;23(3):295-8.
1999: Horn P A; Tesch H; Staib P; Kube D; Diehl V; Voliotis D
Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells.
Blood 1999;93(4):1435-7.
1999: Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
European journal of medical research 1999;4(2):54-8.
1999: Kube D; Vockerodt M; Weber O; Hell K; Wolf J; Haier B; Grässer F A; Müller-Lantzsch N; Kieff E; Diehl V; Tesch H
Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428.
Journal of virology 1999;73(2):1630-6.
1999: Re D; Reiser M; Bamborschke S; Schröder R; Lehrke R; Tesch H; Salzberger B; Diehl V; Fätkenheuer G
Two cases of toxoplasmic encephalitis in patients with acute T-cell leukaemia and lymphoma.
The Journal of infection 1999;38(1):26-9.
1999: Sieber M; Rüffer U; Josting A; Diehl V;
Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 6():23-9.
1999: Staib P; Lathan B; Schinköthe T; Wiedenmann S; Pantke B; Dimski T; Voliotis D; Diehl V
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Advances in experimental medicine and biology 1999;457():437-44.
1998: Söhngen D; Wienen S; Siebler M; Boogen C; Scheid C; Schulz A; Kobbe G; Diehl V; Heyll A
Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination.
Bone marrow transplantation 1998;22(11):1087-90.
1998: Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer J U; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3810-21.
1998: Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk K P; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Blood 1998;92(12):4560-7.
1998: Hegener P; Troke P F; Fätkenheuer G; Diehl V; Ruhnke M
Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.
AIDS (London, England) 1998;12(16):2227-8.
1998: Hombach A; Pohl C; Heuser C; Sircar R; Koch D; Diehl V; Abken H
Generation of the single chain antibody fragment conserves the idiotypic profile of the anti-CD30 monoclonal antibody HRS3.
Scandinavian journal of immunology 1998;48(5):497-501.
1998: Hasenclever D; Diehl V
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
The New England journal of medicine 1998;339(21):1506-14.
1998: Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
Cancer research 1998;58(21):4930-9.
1998: Vockerodt M; Soares M; Kanzler H; Küppers R; Kube D; Hansmann M L; Diehl V; Tesch H
Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease.
Blood 1998;92(8):2899-907.
1998: Hombach A; Pohl C; Heuser C; Sircar R; Diehl V; Abken H
Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies.
Journal of immunological methods 1998;218(1-2):53-61.
1998: Walshe R; Diehl V
[Economic evaluation within the scope of clinical studies]
Der Internist 1998;39(9):943-54.
1998: Fätkenheuer G; Salzberger B; Franzen C; Diehl V
[Clinical studies on the use of protease inhibitors in HIV infection. Answers and questions]
Der Internist 1998;39(9):927-34.
1998: Diehl V; Wolf J; Walshe R; Tesch H; Löffler M
[Therapy of Hodgkin's disease. Optimization over 4 study generations]
Der Internist 1998;39(9):917-26.
1998: Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford J A; Capdeville R; Diehl V; Reyes F
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Blood 1998;92(6):1927-32.
1998: Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann M L; Diehl V; Ghetie V; Engert A
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Leukemia & lymphoma 1998;30(5-6):525-37.
1998: Irsch J; Nitsch S; Hansmann M L; Rajewsky K; Tesch H; Diehl V; Jox A; Küppers R; Radbruch A
Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(17):10117-22.
1998: Hombach A; Sircar R; Heuser C; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H
Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains.
International journal of molecular medicine 1998;2(1):99-103.
1998: Jensen M; Winkler U; Manzke O; Diehl V; Engert A
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab).
Annals of hematology 1998;77(1-2):89-91.
1998: Fätkenheuer G; Salzberger B; Diehl V
[Disseminated infection with Mycobacterium avium complex (MAC) in HIV infection]
Medizinische Klinik (Munich, Germany : 1983) 1998;93(6):360-4.
1998: Kochanek M; Hartmann P; Dölken G; Salzberger B; Diehl V; Fätkenheuer G
Intracerebellar tuberculoma in a patient with AIDS. A case report.
Zentralblatt für Bakteriologie : international journal of medical microbiology 1998;287(4):427-32.
1998: Hegener P; Horst E; Hartmann P; Franzen C; Diehl V; Salzberger B; Fätkenheuer G
Asymptomatic pneumatosis intestinalis and free abdominal air in a patient with AIDS.
European journal of medical research 1998;3(5):265-7.
1998: Walshe R; Engert A; Diehl V
[Current developments in hematology and internal medicine oncology]
Der Internist 1998;39(4):346-54.
1998: Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake P D
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):289-95.
1998: Jox A; Zander T; Kornacker M; Kanzler H; Küppers R; Diehl V; Wolf J
Detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements in a patient with Hodgkin's disease of mixed cellularity subtype at primary diagnosis and in relapse two and a half years later.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(3):283-7.
1998: Müller A; Fätkenheuer G; Salzberger B; Schrappe M; Diehl V; Franzen C
[Strongyloides stercoralis infection in a patient with AIDS and non-Hodgkin lymphoma]
Deutsche medizinische Wochenschrift (1946) 1998;123(13):381-5.
1998: Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
Cancer research 1998;58(6):1116-9.
1998: Loeffler M; Brosteanu O; Hasenclever D; Sextro M; Assouline D; Bartolucci A A; Cassileth P A; Crowther D; Diehl V; Fisher R I; Hoppe R T; Jacobs P; Pater J L; Pavlovsky S; Thompson E; Wiernik P
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):818-29.
1998: Staib P; Lathan B; Knöppel-Schwark S; Tesch H; Voliotis D; Steinmetz H T; Schwonzen M; Wickramanayake P D; Diehl V
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(2):221-3.
1998: Barth S; Huhn M; Wels W; Diehl V; Engert A
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
International journal of molecular medicine 1998;1(1):249-56.
1998: Reiser M; Bruns C; Hartmann P; Salzberger B; Diehl V; Fätkenheuer G
Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1998;17(1):58-60.
1998: Thiele J; Kvasnicka H M; Zirbes T K; Flucke U; Niederle N; Leder L D; Diehl V; Fischer R
Impact of clinical and morphological variables in classification and regression tree-based survival (CART) analysis of CML with special emphasis on dynamic features.
European journal of haematology 1998;60(1):35-46.
1998: Flechtner H; Rüffer J U; Henry-Amar M; Mellink W A; Sieber M; Fermé C; Eghbali H; Josting A; Diehl V
Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S147-54.
1998: Borchmann P; Schnell R; Diehl V; Engert A
New drugs in the treatment of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S103-8.
1998: Wolf J; Tesch H; Parsa-Parsi R; Engert A; Diehl V
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectives.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S79-82.
1998: Loeffler M; Hasenclever D; Diehl V
Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S73-8.
1998: Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rüffer J U; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Dühmke E; Georgii A; Loeffler M
BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S67-71.
1998: Franklin J; Tesch H; Hansmann M L; Diehl V
Lymphocyte predominant Hodgkin's disease: pathology and clinical implication.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S39-44.
1998: Parsa-Parsi R; Engert A; Diehl V
An overview of the Fourth International Symposium on Hodgkin's Disease. Recent advances in basic and clinical research.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 5():S1-3.
1998: Franzen C; Müller A; Hartmann P; Hegener P; Schrappe M; Diehl V; Fätkenheuer G; Salzberger B
Polymerase chain reaction for diagnosis and species differentiation of microsporidia.
Folia parasitologica 1998;45(2):140-8.
1997: Hübel K; Tesch H; Kröger B; Schnell R; Borchmann P; Diehl V; Engert A
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11 Suppl 5():S47-51.
1997: Jox A; Wolf J; Diehl V
Hodgkin's disease biology: recent advances.
Hematological oncology 1997;15(4):165-71.
1997: Barth S; Winkler U; Diehl V; Engert A
[Immunotoxins. Mechanism of action and applications in malignant diseases]
Der Internist 1997;38(11):1063-9.
1997: Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Cancer immunology, immunotherapy : CII 1997;45(3-4):198-202.
1997: Fätkenheuer G; Franzen C; Hartmann P; Wassermann K; Schrappe M; Dölken W; Diehl V; Salzberger B
[Cystic form of Pneumocystis carinii pneumonia]
Deutsche medizinische Wochenschrift (1946) 1997;122(47):1441-6.
1997: Manzke O; Tesch H; Diehl V; Bohlen H
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography.
Journal of immunological methods 1997;208(1):65-73.
1997: von Wasielewski R; Mengel M; Fischer R; Hansmann M L; Hübner K; Franklin J; Tesch H; Paulus U; Werner M; Diehl V; Georgii A
Classical Hodgkin's disease. Clinical impact of the immunophenotype.
The American journal of pathology 1997;151(4):1123-30.
1997: Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H
T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.
Gastroenterology 1997;113(4):1163-70.
1997: Franzen C; Altfeld M; Hegener P; Hartmann P; Arendt G; Jablonowski H; Rockstroh J; Diehl V; Salzberger B; Fätkenheuer G
Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients.
Journal of clinical microbiology 1997;35(10):2639-41.
1997: Schnell R; Barth S; Diehl V; Engert A
Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 1997;8(3):216-34.
1997: Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(5):325-33.
1997: Kvasnicka H M; Thiele J; Werden C; Zankovich R; Diehl V; Fischer R
Prognostic factors in idiopathic (primary) osteomyelofibrosis.
Cancer 1997;80(4):708-19.
1997: Jox A; Zander T; Diehl V; Wolf J
Clonal relapse in Hodgkin's disease.
The New England journal of medicine 1997;337(7):499.
1997: Fätkenheuer G; Arnold G; Steffen H M; Franzen C; Schrappe M; Diehl V; Salzberger B
Invasive amoebiasis in two patients with AIDS and cytomegalovirus colitis.
Journal of clinical microbiology 1997;35(8):2168-9.
1997: Thiele J; Zirbes T K; Lorenzen J; Kvasnicka H M; Scholz S; Erdmann A; Flucke U; Diehl V; Fischer R
Hematopoietic turnover index in reactive and neoplastic bone marrow lesions: quantification by apoptosis and PCNA labeling.
Annals of hematology 1997;75(1-2):33-9.
1997: Reiser M; Fätkenheuer G; Diehl V
Paradoxical expansion of intracranial tuberculomas during chemotherapy.
The Journal of infection 1997;35(1):88-90.
1997: Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze E W
Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2275-87.
1997: Schmitz N; Diehl V
Carmustine and the lungs .
Lancet 1997;349(9067):1712-3.
1997: Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Anticancer research 1997;17(3C):2025-32.
1997: Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity.
Clinical and experimental immunology 1997;108(2):352-7.
1997: Bohlen H; Manzke O; Titzer S; Lorenzen J; Kube D; Engert A; Abken H; Wolf J; Diehl V; Tesch H
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
Cancer research 1997;57(9):1704-9.
1997: Thiele J; Zirbes T K; Lorenzen J; Kvasnicka H M; Dresbach S; Manich B; Leder L D; Niederle N; Diehl V; Fischer R
Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy.
The Journal of pathology 1997;181(3):316-22.
1997: von Wasielewski R; Werner M; Fischer R; Hansmann M L; Hübner K; Hasenclever D; Franklin J; Sextro M; Diehl V; Georgii A
Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group.
The American journal of pathology 1997;150(3):793-803.
1997: Engert A; Schnell R; Barth S; Diehl V
[Immunotherapy strategies in lymphoma]
Der Internist 1997;38(2):150-6.
1997: Drees C; Grond M; Szelies B; Dietlein M; Salzberger B; Diehl V; Heiss W D
[Polyneuropathies in monoclonal gammopathy of undetermined significance: initial manifestation of a lymphoma]
Medizinische Klinik (Munich, Germany : 1983) 1997;92(2):112-6.
1997: Diehl V; Sieber M; Rüffer U; Lathan B; Hasenclever D; Pfreundschuh M; Loeffler M; Lieberz D; Koch P; Adler M; Tesch H
BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):143-8.
1997: Engert A; Schnell R; Küpper F; Reiser M; Engelhard M; Wilhelm M; Lathan B; Baltes-Engler S; Winterhalter B; Scheulen M E; Dederichs B; Tesch H; Wörmann B; Diehl V
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;24(5-6):513-22.
1997: Thiele J; Kvasnicka H M; Fischer R; Diehl V
Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: a concise update.
Leukemia & lymphoma 1997;24(5-6):463-81.
1997: Mucke S; Polack A; Pawlita M; Zehnpfennig D; Massoudi N; Bohlen H; Doerfler W; Bornkamm G; Diehl V; Wolf J
Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells.
Gene therapy 1997;4(2):82-92.
1997: Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig M T; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann M L; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Blood 1997;89(2):403-10.
1997: Jox A; Rohen C; Belge G; Bartnitzke S; Pawlita M; Diehl V; Bullerdiek J; Wolf J
Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 2():131-5.
1997: Winkler U; Barth S; Schnell R; Diehl V; Engert A
The emerging role of immunotoxins in leukemia and lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():139-46.
1996: Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf H J; van Camp B; Urbain J; Diehl V
Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Cytokines and molecular therapy 1996;2(4):231-8.
1996: Schmitz S; Franke H; Loeffler M; Wichmann H E; Diehl V
Model analysis of the contrasting effects of GM-CSF and G-CSF treatment on peripheral blood neutrophils observed in three patients with childhood-onset cyclic neutropenia.
British journal of haematology 1996;95(4):616-25.
1996: Franzen C; Müller A; Salzberger B; Hartmann P; Diehl V; Fätkenheuer G
Uvitex 2B stain for the diagnosis of Isospora belli infections in patients with the acquired immunodeficiency syndrome.
Archives of pathology & laboratory medicine 1996;120(11):1023-5.
1996: Franzen C; Müller A; Hartmann P; Kochanek M; Diehl V; Fätkenheuer G
Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS.
The New England journal of medicine 1996;335(21):1610-1.
1996: Wickramanayake P D; Katay I; Josting A; Diehl V
[Adjuvant systemic therapy of breast carcinoma]
Medizinische Klinik (Munich, Germany : 1983) 1996;91(10):646-53.
1996: Borchmann P; Diehl V; Engert A
[Chronic lymphatic leukemia. Progress in diagnosis and therapy]
Der Internist 1996;37(10):1022-9.
1996: Klimka A; Barth S; Drillich S; Wels W; van Snick J; Renauld J C; Tesch H; Bohlen H; Diehl V; Engert A
A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines.
Cytokines and molecular therapy 1996;2(3):139-46.
1996: Schnell R; Barth S; Diehl V; Engert A
Hodgkin's disease. Future treatment strategies: fact or fiction?
Baillière's clinical haematology 1996;9(3):573-93.
1996: Tesch H; Sieber M; Diehl V
Hodgkin's disease. Treatment of intermediate stages.
Baillière's clinical haematology 1996;9(3):543-51.
1996: Dühmke E; Diehl V; Loeffler M; Mueller R P; Ruehl U; Willich N; Georgii A; Roth S; Matthaei D; Sehlen S; Brosteanu O; Hasenclever D; Wilkowski R; Becker K
Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone.
International journal of radiation oncology, biology, physics 1996;36(2):305-10.
1996: Schwenk A; Höffer-Belitz E; Jung B; Kremer G; Bürger B; Salzberger B; Diehl V; Schrappe M
Resting energy expenditure, weight loss, and altered body composition in HIV infection.
Nutrition (Burbank, Los Angeles County, Calif.) 1996;12(9):595-601.
1996: Klein S C; Kube D; Abts H; Diehl V; Tesch H
Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection.
Leukemia research 1996;20(8):633-6.
1996: Engert A; Reuss K; Tesch H; Diehl V
Third International Symposium on Hodgkin's Lymphoma in Köln, Germany.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1483-5.
1996: Franzen C; Müller A; Hegener P; Hartmann P; Salzberger B; Franzen B; Diehl V; Fätkenheuer G
Polymerase chain reaction for microsporidian DNA in gastrointestinal biopsy specimens of HIV-infected patients.
AIDS (London, England) 1996;10(8):F23-7.
1996: Thiele J; Kvasnicka H M; Werden C; Zankovich R; Diehl V; Fischer R
Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.
Leukemia & lymphoma 1996;22(3-4):303-17.
1996: Thiele J; Zirbes T; Kvasnicka H M; Niederle N; Dammasch J; Schmidt M; Windecker R; Leder L D; Diehl V; Fischer R
Interferon therapy, but not busulfan restores normal-sized megakaryopoiesis in CML--a comparative histo- and immunomorphometric study.
Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1996;11(1):31-42.
1996: Thiele J; Lorenzen J; Zirbes T K; Kvasnicka H M; Schilling C; Schwonzen M; Diehl V; Fischer R
Apoptosis in acute myeloblastic leukemia: follow-up study on trephine biopsies of the bone marrow.
Leukemia & lymphoma 1996;22(1-2):77-82.
1996: Tesch H; Diehl V
Hodgkin's disease: from basic science to clinical application.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10 Suppl 2():s74-7.
1996: Franzen C; Müller A; Diehl V; Schrappe M
[Microsporidia--biology and clinical relevance]
Medizinische Klinik (Munich, Germany : 1983) 1996;91(5):284-94.
1996: Schnell R; Katouzi A A; Linnartz C; Schoen G; Drillich S; Hansmann M L; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel R A; Diehl V; Engert A
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
International journal of cancer. Journal international du cancer 1996;66(4):526-31.
1996: Westermann F; Kube D; Haier B; Bohlen H; Engert A; Zuehlsdorf M; Diehl V; Tesch H
Interleukin 10 inhibits cytokine production of human AML cells.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(4):397-404.
1996: Hartmann F; Pfreundschuh M; Diehl V
[Prognosis and therapy of Hodgkin's disease]
Medizinische Klinik (Munich, Germany : 1983) 1996;91 Suppl 3():75-9.
1996: Winkler U; Bohlen H; Schirrmacher V; Schlimok G; Voliotis D; Brach M; Niederle N; Tesch H; Diehl V; Engert A
[Immunotherapy of hemato-oncologic diseases]
Medizinische Klinik (Munich, Germany : 1983) 1996;91(4):226-33.
1996: Drees C; Postler C; Schwonzen M; Diehl V; Gause A
[Paraproteins and lymphoma in HIV positive patients]
Medizinische Klinik (Munich, Germany : 1983) 1996;91(4):193-8.
1996: Kanzler H; Hansmann M L; Kapp U; Wolf J; Diehl V; Rajewsky K; Küppers R
Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.
Blood 1996;87(8):3429-36.
1996: Wolf J; Kapp U; Bohlen H; Kornacker M; Schoch C; Stahl B; Mücke S; von Kalle C; Fonatsch C; Schaefer H E; Hansmann M L; Diehl V
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.
Blood 1996;87(8):3418-28.
1996: Franzen C; Kuppers R; Muller A; Salzberger B; Fatkenheuer G; Vetten B; Diehl V; Schrappe M
Genetic evidence for latent Septata intestinalis infection in human immunodeficiency virus-infected patients with intestinal microsporidiosis.
The Journal of infectious diseases 1996;173(4):1038-40.
1996: Salzberger B; Franzen C; Fätkenheuer G; Cornely O; Schwenk A; Rasokat H; Diehl V; Schrappe M
CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;11(4):365-9.
1996: Barth S; Schnell R; Diehl V; Engert A
Development of immunotoxins for potential clinical use in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():135-41.
1996: Reuss K; Engert A; Tesch H; Diehl V
Current clinical trials in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():109-13.
1996: Hasenclever D; Loeffler M; Diehl V
Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():95-8.
1996: Sextro M; Diehl V; Franklin J; Hansmann M L; Anagnostopoulos I; Marafioti T; Stein H
Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():61-5.
1996: Wolf J; Bohlen H; Diehl V
Report on the workshop biology of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 4():45-7.
1995: Wickramanayake P D; Scheid C; Josting A; Katay I; Schulz A; Diehl V
Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis.
European journal of medical research 1995;1(3):153-6.
1995: Franzen C; Schwartz D A; Visvesvara G S; Müller A; Schwenk A; Salzberger B; Fätkenheuer G; Hartmann P; Mahrle G; Diehl V
Immunologically confirmed disseminated, asymptomatic Encephalitozoon cuniculi infection of the gastrointestinal tract in a patient with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1995;21(6):1480-4.
1995: Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(9):901-10.
1995: Franzen C; Müller A; Schwenk A; Salzberger B; Fätkenheuer G; Mahrle G; Diehl V; Schrappe M
Intestinal microsporidiosis with Septata intestinalis in a patient with AIDS--response to albendazole.
The Journal of infection 1995;31(3):237-9.
1995: Franzen C; Müller A; Salzberger B; Fätkenheuer G; Eidt S; Mahrle G; Diehl V; Schrappe M
Tissue diagnosis of intestinal microsporidiosis using a fluorescent stain with Uvitex 2B.
Journal of clinical pathology 1995;48(11):1009-10.
1995: Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
International journal of cancer. Journal international du cancer 1995;63(2):304-9.
1995: Schnell R; Linnartz C; Katouzi A A; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch R M; Lange H; Diehl V; Lemke H
Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
International journal of cancer. Journal international du cancer 1995;63(2):238-44.
1995: Fätkenheuer G; Diehl V; Schrappe M
[Clinical aspects and therapy of ubiquitous mycobacterioses]
Der Internist 1995;36(10):987-94.
1995: Wolf J; Jox A; Skarbek H; Pukrop T; Bartnitzke S; Pawlita M; Diehl V; Bullerdiek J
Selective loss of integrated Epstein-Barr virus genomes after long-term cultivation of Burkitt's lymphoma x B-lymphoblastoid cell hybrids due to chromatin instability at the integration site.
Virology 1995;212(1):179-85.
1995: Franzen C; Müller A; Hegener P; Salzberger B; Hartmann P; Fätkenheuer G; Diehl V; Schrappe M
Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus-infected patients by PCR.
Journal of clinical microbiology 1995;33(9):2294-6.
1995: Franzen C; Salzberger B; Fätkenheuer G; Ziegenhagen D; Cornely O; Diehl V; Schrappe M
Stimulated duodenal/bile juice aspiration for diagnosis of enteric pathogens in HIV-infected patients.
Journal of clinical gastroenterology 1995;21(1):33-7.
1995: Nguyen D T; Diamond L W; Schwonzen M; Bohlen H; Diehl V
Chronic lymphocytic leukemia with an interfollicular architecture: avoiding diagnostic confusion with monocytoid B-cell lymphoma.
Leukemia & lymphoma 1995;18(1-2):179-84.
1995: Gorschlüter M; Bohlen H; Hasenclever D; Diehl V; Tesch H
Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):477-82.
1995: Schmitz S; Franke H; Wichmann H E; Diehl V
The effect of continuous G-CSF application in human cyclic neutropenia: a model analysis.
British journal of haematology 1995;90(1):41-7.
1995: Küppers R; Hansmann M L; Diehl V; Rajewsky K
Molecular single-cell analysis of Hodgkin and Reed-Sternberg cells.
Molecular medicine today 1995;1(1):26-30.
1995: Tesch H; Doerfler W; Engert A; Hansmann M; Radbruch A; Rajewsky K; Wolf J; Diehl V
[Immune dysregulation and malignant lymphoma]
Der Internist 1995;36(4):367-71.
1995: Zirbes T K; Engert A; Thiele J; Diehl V
[Sarcoidosis and chronic idiopathic thrombocytopenic purpura]
Medizinische Klinik (Munich, Germany : 1983) 1995;90(3):138-40.
1995: Thiele J; Kvasnicka H M; Niederle N; Zirbes T K; Schmidt M; Dammasch J; Meuter B R; Leder L D; Kloke O; Diehl V
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.
Annals of hematology 1995;70(3):121-8.
1995: Munker R; Hasenclever D; Brosteanu O; Hiller E; Diehl V
Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):403-9.
1995: Wolf J; Draube A; Bohlen H; Jox A; Mücke S; Pawlita M; Möller P; Diehl V
Suppression of Burkitt's lymphoma tumorigenicity in nude mice by co-inoculation of EBV-immortalized lymphoblastoid cells.
International journal of cancer. Journal international du cancer 1995;60(4):527-33.
1995: Schmitz S; Wolf J; Diehl V
[Etiological assessment of lymphadenopathy]
Der Internist 1995;36(2):139-45.
1995: Steinmetz H T; Herbertz A; Bertram M; Diehl V
Increase in interleukin-6 serum level preceding fever in granulocytopenia and correlation with death from sepsis.
The Journal of infectious diseases 1995;171(1):225-8.
1995: Hasenclever D; Schmitz N; Diehl V
Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG).
Leukemia & lymphoma 1995;15 Suppl 1():47-9.
1995: Wolf J; Diehl V
Biology and therapy of Hodgkin's disease.
European journal of cancer (Oxford, England : 1990) 1995;31A(5):830-1.
1994: Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate U C; Hansmann M L; Wacker H H; Berthold F; Diehl V; Engert A
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Cancer research 1994;54(23):6186-93.
1994: Salzberger B; Schrappe M; Diehl V
[Antiretroviral therapy in adult HIV-infected patients]
Der Internist 1994;35(12):1095-104.
1994: Spickermann D; Gause A; Pfreundschuh M; Von Kalle A K; Bohlen H; Diehl V
Impaired antibody levels to tetanus toxoid and pneumococcal polysaccharides in acute leukemias.
Leukemia & lymphoma 1994;16(1-2):89-96.
1994: Schmitz S H; Voliotis D L; Schimke J; Diehl V
Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma.
Oncology 1994;51(6):502-6.
1994: Bartels C; Hönig R; Burger G; Diehl V; de Vivie R
The significance of anticardiolipin antibodies and anti-heart muscle antibodies for the diagnosis of postpericardiotomy syndrome.
European heart journal 1994;15(11):1494-9.
1994: Engert A; Schnell R; Lathan B; Diehl V
[Limits and value of chemotherapy in elderly patients]
Medizinische Klinik (Munich, Germany : 1983) 1994;89(11):603-10.
1994: Bürger B; Schwenk A; Jünger H; Ollenschläger G; Wessel D; Diehl V; Schrappe M
Oral supplements in HIV-infected patients with chronic wasting. A prospective trial.
Medizinische Klinik (Munich, Germany : 1983) 1994;89(11):579-81, 633.
1994: Franzen C; Fätkenheuer G; Salzberger B; Müller A; Mahrle G; Diehl V; Schrappe M
Intestinal microsporidiosis in patients with acquired immunodeficiency syndrome--report of three more German cases.
Infection 1994;22(6):417-9.
1994: Diehl V; Marty M
Efficacy and safety of antiemetics.
Cancer treatment reviews 1994;20(4):379-92.
1994: Schmitz S H; Scheding S; Voliotis D; Rasokat H; Diehl V; Schrappe M
Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood.
Annals of hematology 1994;69(3):135-8.
1994: Tacke W; Kruis W; Zehnter E; Ziegenhagen D; Velasco S; Diehl V
[Endosonographic findings in the upper gastrointestinal tract in staging of malignant nodal and extranodal lymphomas]
Zeitschrift für Gastroenterologie 1994;32(8):431-5.
1994: Bohlen H; Manzke O; Engert A; Hertel M; Hippler-Altenburg R; Diehl V; Tesch H
Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation.
Journal of immunological methods 1994;173(1):55-62.
1994: Thiele J; Chen Y S; Kvasnicka H M; Diehl V; Fischer R
Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis--a histomorphometric study on sequential trephine biopsies.
Leukemia & lymphoma 1994;14(1-2):163-9.
1994: Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Science (New York, N.Y.) 1994;264(5160):833-5.
1994: Engert A; Gottstein C; Winkler U; Amlot P; Pileri S; Diehl V; Thorpe P
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Leukemia & lymphoma 1994;13(5-6):441-8.
1994: Schobert I; Renner C; Pfreundschuh M; Diehl V; Pohl C
Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin's lymphoma.
Leukemia & lymphoma 1994;13(5-6):429-40.
1994: Diehl V; Engert A
[Controversies in therapy of malignant lymphomas]
Der Internist 1994;35(4):313-22.
1994: Schmitz S; Tesch H; Bohlen H; Engert A; Diehl V
[Chronic fatigue syndrome]
Medizinische Klinik (Munich, Germany : 1983) 1994;89(3):154-9.
1994: Jücker M; Günther A; Gradl G; Fonatsch C; Krueger G; Diehl V; Tesch H
The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma.
Leukemia research 1994;18(1):7-16.
1994: Winkler U; Gottstein C; Schön G; Kapp U; Wolf J; Hansmann M L; Bohlen H; Thorpe P; Diehl V; Engert A
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
Blood 1994;83(2):466-75.
1994: Trümper L; Jung W; Dahl G; Diehl V; Gause A; Pfreundschuh M
Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():93-6.
1994: Wolf J; Diehl V
Is Hodgkin's disease an infectious disease?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():105-11.
1994: Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
Immunotoxins: is there a clinical value?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 1():97-103.
1993: Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
International journal of cancer. Journal international du cancer 1993;55(5):830-6.
1993: Schwenk A; Büger B; Wessel D; Stützer H; Ziegenhagen D; Diehl V; Schrappe M
Clinical risk factors for malnutrition in HIV-1-infected patients.
AIDS (London, England) 1993;7(9):1213-9.
1993: Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake P D; Diehl V; Tesch H
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Blood 1993;82(6):1803-12.
1993: Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Cancer research 1993;53(18):4310-4.
1993: Renner C; Pfreundschuh M; Diehl V; Pohl C
Active specific immunotherapy of Hodgkin's lymphoma by an anti-idiotype vaccine against the Hodgkin-associated CD30 antigen.
Annals of the New York Academy of Sciences 1993;690():352-4.
1993: Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
International journal of cancer. Journal international du cancer 1993;54(5):820-7.
1993: Tesch H; Günther A; Abts H; Jücker M; Klein S; Krueger G R; Diehl V
Expression of interleukin-2R alpha and interleukin-2R beta in Hodgkin's disease.
The American journal of pathology 1993;142(6):1714-20.
1993: Wolf J; Pawlita M; Jox A; Kohls S; Bartnitzke S; Diehl V; Bullerdiek J
Integration of Epstein Barr virus near the breakpoint of a translocation 11;19 in a Burkitt's lymphoma cell line.
Cancer genetics and cytogenetics 1993;67(2):90-4.
1993: Thiele J; Kvasnicka H M; Titius B R; Parpert U; Nebel R; Zankovich R; Dienemann D; Stein H; Diehl V; Fischer R
Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.
Annals of hematology 1993;66(6):291-302.
1993: Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
International journal of cancer. Journal international du cancer 1993;54(3):418-25.
1993: Franzen C; Fätkenheuer G; Salzberger B; Ziegenhagen D; Seitz H M; Diehl V; Schrappe M
[Isospora belli infection in an AIDS patient]
Medizinische Klinik (Munich, Germany : 1983) 1993;88(5):330-2.
1993: Steinmetz H T; Mantovani L; Diehl V
[Clinical importance of colony stimulating factors]
Medizinische Klinik (Munich, Germany : 1983) 1993;88(3):146-54.
1993: Diehl V
Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG).
Annals of hematology 1993;66(3):139-40.
1993: Schwonzen M; Pohl C; Steinmetz T; Seckler W; Vetten B; Thiele J; Wickramanayake D; Diehl V
Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification.
British journal of haematology 1993;83(2):232-9.
1993: Tesch H; Stein H; Diehl V
[Cellular and molecular biology of malignant lymphoma]
Der Internist 1993;34(2):89-96.
1993: Lathan B; Pfreundschuh M; Diehl V
[Therapeutic strategies of Hodgkin's disease]
Der Internist 1993;34(2):146-54.
1993: Wolf J; Pawlita M; Klevenz B; Frech B; Freese U K; Müller-Lantzsch N; Diehl V; zur Hausen H
Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells.
International journal of cancer. Journal international du cancer 1993;53(4):621-7.
1993: Bürger B; Ollenschläger G; Schrappe M; Stute A; Fischer M; Wessel D; Schwenk A; Diehl V
Nutrition behavior of malnourished HIV-infected patients and intensified oral nutritional intervention.
Nutrition (Burbank, Los Angeles County, Calif.) 1993;9(1):43-4.
1993: Peest D; Coldewey R; Deicher H; Sailer M; Vykoupil C; Leo R; Georgii A; Karow J; Hoeppner E; Diehl V
Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.
European journal of cancer (Oxford, England : 1990) 1993;29A(7):978-83.
1993: Volling P; Jungehülsing M; Jücker M; Stützer H; Diehl V; Tesch H
Coamplification of the hst and bcl-1 oncogenes in advanced squamous cell carcinomas of the head and neck.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):383-9.
1992: Petit M; Wassermann K; Vierbuchen M; Schell-Frederick E; Fischer R; Bolte A; Diehl V
[Non-puerperal granulomatous mastitis: sarcoidosis or nonspecific inflammatory reaction?]
Medizinische Klinik (Munich, Germany : 1983) 1992;87(12):663-6.
1992: Schrappe M; Wassermann K; Ziegenhagen D; Salzberger B; Fätkenheuer G; Schwenk A; Hiersche A; Diehl V
[Pneumocystis carinii in oncologic diseases]
Medizinische Klinik (Munich, Germany : 1983) 1992;87 Suppl 1():65-70.
1992: Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
[New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?]
Medizinische Klinik (Munich, Germany : 1983) 1992;87(10):503-9.
1992: Kapp U; Wolf J; von Kalle C; Tawadros S; Röttgen A; Engert A; Fonatsch C; Stein H; Diehl V
Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():21-3.
1992: Tesch H; Feller A C; Jücker M; Klein S; Merz H; Diehl V
Activation of cytokines in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():13-6.
1992: Diehl V; Engert A
An overview of the Second International Symposium on Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():1-3.
1992: Engert A; Pohl C; Diehl V
Experimental therapy in Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():97-100.
1992: da Costa L; Carde P; Lumbroso J D; Ricard M; Pfreundschuh M; Bosq J; Manil L; Diehl V; Parmentier C
Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():53-7.
1992: Gause A; Jung W; Schmits R; Tschiersch A; Scholz R; Pohl C; Hasenclever D; Diehl V; Pfreundschuh M
Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():49-52.
1992: Pfreundschuh M; Lathan B; Löffler M; Rüffer U; Hasenclever D; Diehl V
The Second International Symposium on Hodgkin's Disease. Workshop III: Recommendations for future clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 4():101-4.
1992: Koch K; Tesch H; Eidt S; Krueger G; Diehl V
Analysis of c-myc, bcl-1 and bcl-2 translocations in human lymphoma by pulsed-field gel electrophoresis.
Leukemia & lymphoma 1992;7(5-6):463-72.
1992: Ollenschläger G; Thomas W; Konkol K; Diehl V; Roth E
Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia.
European journal of clinical investigation 1992;22(8):546-53.
1992: Franzen D; Curtius J M; Heitz W; Höpp H W; Diehl V; Hilger H H
Cardiac involvement during and after malaria.
The Clinical investigator 1992;70(8):670-3.
1992: Gause A; Jung W; Keymis S; Schobert I; Scholz R; Schmits R; Diehl V; Pohl C; Hasenclever D; Pfreundschuh M
The clinical significance of cytokines and soluble forms of membrane-derived activation antigens in the serum of patients with Hodgkin's disease.
Leukemia & lymphoma 1992;7(5-6):439-47.
1992: Tesch H; Jücker M; Klein S; Abts H; Günther A; Krueger G R; Diehl V
Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors.
Leukemia & lymphoma 1992;7(4):297-303.
1992: Schwonzen M; Pohl C; Steinmetz T; Wickramanayake P D; Thiele J; Diehl V
Bone marrow involvement in non-Hodgkin's lymphoma: increased diagnostic sensitivity by combination of immunocytology, cytomorphology and trephine histology.
British journal of haematology 1992;81(3):362-9.
1992: Jücker M; Roebroek A J; Mautner J; Koch K; Eick D; Diehl V; Van de Ven W J; Tesch H
Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell lines.
Oncogene 1992;7(5):943-52.
1992: Gause A; Keymis S; Scholz R; Schobert I; Jung W; Diehl V; Pohl C; Pfreundschuh M
Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.
Lymphokine and cytokine research 1992;11(2):109-13.
1992: Schwonzen M; Schmits R; Baldus S E; Vierbuchen M; Hanisch F G; Pfreundschuh M; Diehl V; Bara J; Uhlenbruck G
Monoclonal antibody FW6 generated against a mucin-carbohydrate of human amniotic fluid recognises a colonic tumour-associated epitope.
British journal of cancer 1992;65(4):559-65.
1992: Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
International journal of cancer. Journal international du cancer 1992;50(6):958-67.
1992: Pohl C; Schobert I; Moter A; Woll E M; Schwonzen M; Hiersche A; Diehl V
Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):172-3.
1992: Linden A; Gückel C; Widder R; Jungehülsing M; Diehl V; Schicha H
[NMR tomography in plasmacytoma]
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1992;156(1):83-8.
1992: Hönig R; Gause A; Krueger G; Voliotis D; Zehnter E; Diehl V
[Midline granuloma in a Korean patient]
Medizinische Klinik (Munich, Germany : 1983) 1992;87(1):16-20.
1992: Tesch H; Michels M; Jücker M; Pahl I; Klein S; Bading H; Moelling K; Diehl V
Heterogeneous expression of c-myb protein in human leukemia detected by simultaneous two color flow cytometric analysis.
Leukemia research 1992;16(3):265-74.
1992: Gause A; Schmitz G; von Kalle A K; Lathan B; Diehl V; Pfreundschuh M
The clinical relevance of IgG subclasses in acute leukemias: low serum IgG as a risk factor for early death due to infection in acute myelogenous leukemia.
Leukemia research 1992;16(2):165-71.
1992: Kapp U; Wolf J; von Kalle C; Stein H; Fonatsch C; Schell-Frederick E; Diehl V
Recent efforts to establish an in vivo model as a new experimental tool in the study of Hodgkin's disease.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1408-11.
1992: von Kalle C; Diehl V
Hodgkin's disease: analysis of cell line data.
International review of experimental pathology 1992;33():185-203.
1991: Schrappe M; Pohl C; Tesch H; Diehl V
[HIV-associated non-hodgkin lymphoma. Prognosis and therapeutic options]
Medizinische Klinik (Munich, Germany : 1983) 1991;86(12):646-54, 660.
1991: Tacke W; Kruis W; Zehnter E; Ziegenhagen D; Diehl V
[Endoscopic ultrasonography--possibilities and limitations in the gastrointestinal tract]
Medizinische Klinik (Munich, Germany : 1983) 1991;86(12):639-45.
1991: Gause A; Scholz R; Klein S; Jung W; Diehl V; Tesch H; Hasenclever D; Pfreundschuh M
Increased levels of circulating interleukin-6 in patients with Hodgkin's disease.
Hematological oncology 1991;9(6):307-13.
1991: Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
International journal of cancer. Journal international du cancer 1991;49(3):450-6.
1991: Gause A; Verpoort K; Roschansky V; Tschiersch A; Hasenclever D; Schmits R; Diehl V; Brosteanu O; Pfreundschuh M
The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(8):579-83.
1991: Pohl C; Pollok M; Franzen D; Gause A; Diehl V
[Type II mixed cryoglobulinemia in chronic hepatitis]
Medizinische Klinik (Munich, Germany : 1983) 1991;86(8):410-3.
1991: Wickramanayake P D; Pallenschat J; Diehl V
[Chronic myelomonocytic leukemia--myelodysplastic syndrome]
Medizinische Klinik (Munich, Germany : 1983) 1991;86(8):383-6.
1991: Hartmann F; Gheorghiu T; Leupold H; Baer F; Diehl V
Serratia infections in patients with neutropenia.
Klinische Wochenschrift 1991;69(11):491-4.
1991: Tesch H; Lathan B; Diehl V
[Malignant lymphomas in HIV infected patients]
Der Internist 1991;32(8):495-8.
1991: Achten S; Behn-Krappa A; Jücker M; Sprengel J; Hölker I; Schmitz B; Tesch H; Diehl V; Doerfler W
Patterns of DNA methylation in selected human genes in different Hodgkin's lymphoma and leukemia cell lines and in normal human lymphocytes.
Cancer research 1991;51(14):3702-9.
1991: Schell-Frederick E; Karrenbrock G; Tepass T; Risch E; Diehl V
Identification and quantification of human peripheral blood lymphocytes and monocytes following migration into nitrocellulose filters.
Journal of immunological methods 1991;139(1):25-30.
1991: Tesch H; Fonatsch C; Diehl V
Rearrangements of immunoglobulin- and BCR-genes in chronic myeloid leukemia.
In vivo (Athens, Greece) 1991;5(3):233-8.
1991: Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Blood 1991;77(9):1983-8.
1991: Zehnter E; Seifert H; Petit M; Plum G; Peters G; Diehl V
[A protracted course in Cardiobacterium hominis endocarditis]
Deutsche medizinische Wochenschrift (1946) 1991;116(20):768-71.
1991: Pohl C; Sieber M; Diehl V; Pfreundschuh M
Idiotype vaccine against Hodgkin's lymphoma: generation and characterization of an anti-idiotypic monoclonal antibody against the Hodgkin-associated (anti-CD 30) monoclonal antibody HRS-3.
Anticancer research 1991;11(3):1115-24.
1991: Wickramanayake P D; Pallenschat J; Diehl V
[Myelodysplastic syndrome (preleukemia)]
Medizinische Klinik (Munich, Germany : 1983) 1991;86(3):157-64.
1991: Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2 Suppl 2():43-7.
1991: Abts H; Jücker M; Diehl V; Tesch H
Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr.
Leukemia research 1991;15(11):987-97.
1990: Diehl V; von Kalle C; Fonatsch C; Tesch H; Jüecker M; Schaadt M
The cell of origin in Hodgkin's disease.
Seminars in oncology 1990;17(6):660-72.
1990: Engert A; Lathan B; Cremer R; Seeber S; Schulte M; Diehl V
[Non-Hodgkin lymphoma and pregnancy]
Medizinische Klinik (Munich, Germany : 1983) 1990;85(12):734-8.
1990: Sahin U; Hartmann F; Senter P; Pohl C; Engert A; Diehl V; Pfreundschuh M
Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.
Cancer research 1990;50(21):6944-8.
1990: Wassermann K; Pothoff G; Heitz W; Kirn E; Krueger G R; Diehl V; Eckert G; Hilger H H
[Acute pneumocystosis during polychemotherapy following the MACOP-B protocol]
Deutsche medizinische Wochenschrift (1946) 1990;115(45):1705-11.
1990: Bungart B; Loeffler M; Goris H; Dontje B; Diehl V; Nijhof W
Differential effects of recombinant human colony stimulating factor (rh G-CSF) on stem cells in marrow, spleen and peripheral blood in mice.
British journal of haematology 1990;76(2):174-9.
1990: Michels M; Schumacher E; Diehl V; Tesch H
[Plasmocytoma: immunology and molecular genetics]
Medizinische Klinik (Munich, Germany : 1983) 1990;85(9):548-54.
1990: Katay I; Wirnitzer U; Burrichter H; von Kalle C; Schell-Frederick E; Diehl V; Schaadt M
L428 cells derived from Hodgkin's disease produce E rosette-inhibiting factor.
Blood 1990;76(4):791-6.
1990: Lathan B; Kerkhoff K; Scheithauer W; Diehl V
In vitro drug sensitivity testing with agar-containing glass capillaries.
Anticancer research 1990;10(4):1075-8.
1990: Jücker M; Schaadt M; Diehl V; Poppema S; Jones D; Tesch H
Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines.
Hematological oncology 1990;8(4):191-204.
1990: Pfreundschuh M; Pohl C; Berenbeck C; Schroeder J; Jung W; Schmits R; Tschiersch A; Diehl V; Gause A
Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis.
International journal of cancer. Journal international du cancer 1990;45(5):869-74.
1990: Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu S M; Diehl V; Thorpe P
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Cancer research 1990;50(10):2929-35.
1990: Engert A; Burrows F; Jung W; Tazzari P L; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Cancer research 1990;50(1):84-8.
1990: Tesch H; Herrmann T; Abts H; Diamantstein T; Diehl V
High affinity IL-2 receptors on a Hodgkin's derived cell line.
Leukemia research 1990;14(11-12):953-60.
1990: Tesch H; Zankovich R; Fonatsch C; Diehl V
Analysis of bcr rearrangements in primary (essential) thrombocythaemia.
Leukemia research 1990;14(3):241-6.
1990: Tesch H; May P; Krueger G R; Fischer R; Diehl V
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Oncology 1990;47(3):215-23.
1990: Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Kirchner H
Cooperative trials of Hodgkin's lymphoma in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):106-8.
1989: Tesch H; Abts H; Jücker M; Mays K; Lenoir G; Diehl V
Expression of c-fgr in EBV positive and negative B cell tumors.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(12):897-8.
1989: Linden A; Zankovich R; Theissen P; Diehl V; Schicha H
Malignant lymphoma: bone marrow imaging versus biopsy.
Radiology 1989;173(2):335-9.
1989: Lathan B; Kerkhoff K; Scheithauer W; Von Hoff D D; Diehl V
Homogeneous growth of tumor cell colonies in agar containing glass capillaries.
Anticancer research 1989;9(6):1897-902.
1989: Pfreundschuh M; Diehl V
[Palliative medical therapy of malignant diseases]
Deutsche medizinische Wochenschrift (1946) 1989;114(46):1797-803.
1989: Linden A; Zankovich R; Theissen P; Schauerte G; Diehl V; Schicha H
[Bone marrow scintigraphy and magnetic resonance tomography in malignant lymphomas: comparison with histologic results]
Nuklearmedizin. Nuclear medicine 1989;28(5):166-71.
1989: Schell-Frederick E; Tepass T; Lorscheidt G; Pfreundschuh M; Schaadt M; Diehl V
Effects of recombinant tumor necrosis factor (rHuTNF alpha) on human neutrophils and monocytes: in vitro, ex vivo and in vivo.
European journal of haematology 1989;43(4):286-96.
1989: Thiele J; Zankovich R; Steinberg T; Fischer R; Diehl V
Agnogenic myeloid metaplasia (AMM)--correlation of bone marrow lesions with laboratory data: a longitudinal clinicopathological study on 114 patients.
Hematological oncology 1989;7(5):327-43.
1989: Pfreundschuh M; Carde P; Da Costa L; Manil L; Lumbroso J D; Caillou B; Boudet F; Ricard M; Hayat M; Diehl V
[In vivo imaging of Hodgkin's lymphomas using monoclonal antibodies]
Onkologie 1989;12 Suppl 1():30-3.
1989: Pfreundschuh M; Diehl V
[Therapy of recurrent Hodgkin's lymphoma. II. The value of bone marrow transplantation]
Deutsche medizinische Wochenschrift (1946) 1989;114(23):916-21.
1989: Pfreundschuh M; Diehl V
[Therapy of recurrent Hodgkin's lymphoma. I. Radiotherapy and conventional chemotherapy]
Deutsche medizinische Wochenschrift (1946) 1989;114(22):880-4.
1989: Pfreundschuh M; Genth B; Kirchner H; Scheurich P; Lindemann A; Steinmetz H T; Schaadt M; Diehl V
[Mechanism of resistance to tumor necrosis factor]
Onkologie 1989;12(3):128-30.
1989: von Kalle A K; Schaadt M; Diehl V
European experience with ifosfamide in lymphomas.
Seminars in oncology 1989;16(1 Suppl 3):73-7.
1989: Schaadt M; Burrichter H; Pfreundschuh M; Schell-Frederick E; Tesch H; Fonatsch C; Stein H; Diehl V
Biology of Hodgkin cell lines.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():53-61.
1989: Armitage J O; Barnett M J; Carella A M; Dicke K A; Diehl V; Gribben J G; Pfreundschuh M
Bone marrow transplantation in the treatment of Hodgkin's lymphoma: problems, remaining challenges, and future prospects.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():246-53.
1989: Schicha H; Franke M; Smolorz J; Linden A; Waters W; Diehl V
Diagnostic strategies and staging procedures for Hodgkin's lymphoma: bone marrow scintigraphy and magnetic resonance imaging.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():112-9.
1989: Carde P; Pfreundschuh M; da Costa L; Manil L; Lumbroso J D; Caillou B; Parmentier C; Saccavini J C; Diehl V
Radiolabeled monoclonal antibodies against Reed-Sternberg cells for in vivo imaging of Hodgkin's disease by immunoscintigraphy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1989;117():101-11.
1989: Widding A; Smolorz J; Franke M; Linden A; Diehl V; Schicha H
Bone marrow investigation with technetium-99m microcolloid and magnetic resonance imaging in patients with malignant myelolympho-proliferative diseases.
European journal of nuclear medicine 1989;15(5):230-8.
1989: Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
Acta haematologica 1989;81(4):192-202.
1989: Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S
Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
Medical oncology and tumor pharmacotherapy 1989;6(2):155-62.
1988: Thiele J; Zankovich R; Schneider G; Kremer B; Fischer R; Diehl V
Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1988;10(5):375-82.
1988: Zankovich R; Diehl V
[Clinical characterization of essential thrombocythemia in comparison to other myeloproliferative diseases and reactive thrombocytoses]
Klinische Wochenschrift 1988;66(15):699-702.
1988: Tesch H; Jücker M; Falk M H; Bornkamm G W; Jones D B; Diehl V
Molecular analysis of Hodgkin's disease-derived cell lines.
Hematological oncology 1988;6(3):223-31.
1988: Schell-Frederick E; Radtke H; Sommer H; Helbing I; Burrichter H; Schaadt M; Diehl V
Inhibition of human neutrophil migration by supernatants from Hodgkin's disease-derived cell lines.
European journal of clinical investigation 1988;18(3):290-6.
1988: Mertens T; Diehl V
[Prevention of HIV infection in the clinic and general practice]
Der Internist 1988;29(2):131-8.
1988: Schell-Frederick E; Ziffling P; Sommer H; Radtke H; Diehl V
Cell migration in patients with Hodgkin's disease.
Acta paediatrica Hungarica 1988;29(1-2):213-6.
1987: Pfreundschuh M G; Schoppe W D; Fuchs R; Pflüger K H; Loeffler M; Diehl V
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Cancer treatment reports 1987;71(12):1203-7.
1987: Diehl V; Pfreundschuh M; Löffler M; Smith K; Rühl U; Georgii A; Hiller E; Gerhartz H
[Therapy studies of the German Hodgkin's Study Group. Intermediate results of the study protocols HD1, HD2, and HD3]
Onkologie 1987;10(2):62-6.
1986: Diehl V; Pfreundschuh M; Hauser F E; Löffler M; Rühl U; Brücher H; Georgii A; Hiller E; Gerhartz H
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group]
Medizinische Klinik (Munich, Germany : 1983) 1986;81(1):1-6.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Volker Diehl

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Living Beings

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Volker Diehl (preview)

All Publications